AIM Vaccine
Full Industry Chain Vaccine Group

AIM Vaccine Co., Ltd.

(A joint stock company incorporated in the People's Republic of China with limited liability)
Stock Code: 06660







2025

Environmental, Social and Governance Report

CONTENTS

About the Report 01

Board ESG Management Statement 03

About AIM Vaccine 04

ESG Management 09

01 **Sound Governance for Steady Progress and Long-term Success**

Corporate Governance 12

Protection of Investor Rights 13

Compliant Operations 14

Business Ethics 15

02 **Innovation-Led, R&D-Driven**

R&D and Innovation 17

Intellectual Property Protection 21

Medical Research Ethics 22

ESG Data Tables and Notes 59

Benchmarking Index Table 67



03 Quality First, Striving for Excellence

Product Safety and Quality 26
Customer Service Management 31
Information Security and Privacy Protection 33
Supplier Management 34

04 Green and Low-Carbon Development, Living in Harmony

Environmental Management 36
Resource Utilisation 37
Emissions Management 39
Response to Climate Change 42

05 People-Centred Approach, Empowering Employees

Employee Recruitment and Rights 46
Human Capital Development 49
Work Safety 51

06 Committed to Public Welfare, Making Health Care Accessible

Community Investment and Public Welfare 55
Access to Healthcare 57

About the Report

This report is the fourth *Environmental, Social and Governance (ESG) Report* of AIM Vaccine Co., Ltd. (AIM Vaccine or the Group), disclosing to investors and other stakeholders its principles on ESG topics, management approaches established, work implemented, and results achieved in operations.

Report Scope

The scope of this report covers AIM Vaccine Co., Ltd. Unless otherwise stated, it is consistent with the scope of the consolidated financial statements of AIM Vaccine (Stock Code: 6660.HK) for the same period.

List of Full Company Names and Abbreviations

Full Name	Abbreviation
AIM Vaccine Co., Ltd.	AIM Vaccine, the Group, Group, Company, We
AIM Rongyu (Ningbo) Biopharmaceutical Co., Ltd.	AIM Rongyu
AIM Honesty Biopharmaceutical Co., Ltd.	AIM Honesty
AIM Persistence Biopharmaceutical Co., Ltd.	AIM Persistence
AIM Action BioPharm Co., Ltd.	AIM Action
AIM Explorer Biomedical R&D Co., Ltd.	AIM Explorer
Liverna Therapeutics Inc.	AIM Liverna
AIM Innovator Biomedical Research (Shanghai) Co., Ltd.	AIM Innovator
AIM Leader (Beijing) Biomedical Research Co., Ltd.	AIM Leader

Reporting Period

The reporting period was from 1 January 2025 to 31 December 2025 (hereinafter referred to as the reporting period). Unless otherwise specified, the data and textual information in this report are all figures for this period.

Basis for Preparation

This report was prepared in accordance with the requirements of the *Environmental, Social and Governance Reporting Rules* (version effective from 1 January 2025) issued by The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "HKEX").

Reporting Preparation

Principle of materiality

The Company has identified the materiality topics related to operations that are of concern to various stakeholders, which serve as the focus of this report. While reporting on the materiality topics in this report, we also took into account the characteristics of our industry and business operations. For details of the topic materiality analysis process and results, please refer to the “Analysis of Materiality Topics” section of this report.

Principle of accuracy

This report endeavors to ensure the accuracy of the information. The measurement results of quantitative information are presented with explanations of data standard, calculation bases, and assumptions to ensure that calculation errors will not mislead information users. Quantitative information and notes are detailed in the "ESG Data Tables and Notes" section of this report. The Board of Directors guarantees the content of this report and confirms that there are no false records, misleading statements, or significant omissions.

Principle of balance

The content of this report reflects objective and true facts, and presents balanced disclosures of both positive and negative information relating to the Company. During the reporting period, no negative incidents that should have been disclosed but were not disclosed were identified.

Principle of clarity

This report was published in Traditional Chinese and English versions, and includes information such as tables and model diagrams as supplementary material to the written content of this report, facilitating stakeholders' better understanding of the written content. To enable stakeholders to access information more quickly, this report provides a table of contents and a benchmarking index table aligning with ESG standards.

Principle of quantifiability

This report discloses key quantitative disclosure items and, where practicable, provides historical data. For further details, please refer to the "ESG Data Tables and Notes" section.

Principle of comparability

For the same quantitative disclosure items, this report maintains consistency in statistical methods and disclosure approaches across different reporting periods. Where there are changes in data collection, measurement, or calculation methods, retrospective adjustments are made to the relevant data, and the nature of and reasons for such adjustments are explained in the notes to the report, in order to enable stakeholders to conduct meaningful analysis and assess trends in the development of the Company's ESG data performance.

Principle of completeness

The scope of disclosures in this report is consistent with the scope of the Company's consolidated financial statements.

Principle of timeliness

This report is an annual report covering the period from 1 January 2025 to 31 December 2025. The Company strove to publish the report as soon as practicable after the end of the reporting year to provide timely information for stakeholders' decision-making.

Principle of verifiability

The cases and data in this report are derived from original records or financial reports from the Company's actual operations. The sources of the disclosed data and the calculation processes are all traceable.

Data Explanation

The data and case in the Report are derived from official records of the Company's actual operations, and all financial data are denominated in RMB. In case of any discrepancies between the financial data and the Company's annual financial report, the annual financial report shall prevail.

Access to the Report

This report is published in electronic form. The publication platforms include the information disclosure platform designated by the Stock Exchange. It is also available for online viewing or download on the Group's official website (https: //www.aimbio.com/index.html). If you have any suggestions regarding the report, please contact us at the following email address: aim.securities@aimbio.com

Board ESG Management Statement

Sustainable development is an important foundation for the long-term, steady operation of biopharmaceutical enterprises. It is also an intrinsic requirement for the Group to fulfil our corporate mission and safeguard public health. The Board of Directors of AIM Vaccine attaches great importance to environmental, social and governance (ESG) work, and continues to improve our governance structure, strengthen risk management and deepen responsible practices, thereby promoting high-quality and sustainable corporate development.

Board Responsibilities: As the highest decision-making and oversight body for the Group' s ESG governance, the Board bears ultimate responsibility for sustainable development. It is responsible for approving the ESG strategy, plans, and material matters, regularly assessing the achievement of targets, and ensuring the effective operation of the risk management system.

ESG Management Policy and Strategy: The Board of Directors fully recognised that ESG management is a core cornerstone for achieving sustainable development and for effectively identifying and addressing risks and opportunities across governance, environmental and social dimensions. The Board of Directors, guided by the core philosophy of "developing and manufacturing top quality vaccines to safeguard the health of the world" , took the lead in establishing a comprehensive ESG strategy and policy framework, deeply embedding ESG principles throughout the entire corporate governance process, and setting up a three-tier management framework of "supervision by the Board of Directors-ESG working group coordination-collaboration among various functional departments/branches/subsidiaries" , thereby providing a solid safeguard for long-term steady development and responsible operations.

ESG Risk Management: Each year, the Board of Directors conducts a comprehensive assessment of the materiality of ESG topics in light of the Company' s stage of development, dynamically adjusts the risk management plan, and ensures that ESG work is deeply aligned with the Group' s strategic operations. The Board of Directors drove the establishment of a full-process risk management and control mechanism, fully integrating sustainable development risks into the enterprise risk management system. Through routine supervision and process control, we effectively prevented and controlled risks and seized green development opportunities.

Material ESG Topics: The Board of Directors promotes the establishment of a transparent and efficient stakeholder communication mechanism. Through internal collaboration and external cooperation, we systematically identify material ESG topics and prioritise them based on their potential impacts and level of risk, providing a sound basis for the Group to set ESG targets and conduct regular assessments.

This report truthfully discloses the progress and achievements of the Group' s ESG work, and was published after being reviewed and approved by the Board of Directors.

01 About AIM Vaccine

Company Profile

AIM Vaccine Co., Ltd. was established in 2011. With developing and manufacturing top quality vaccines to safeguard the health of the world as our mission, we are a leading enterprise in the vaccine industry in China. The Group has four wholly-owned licensed vaccine manufacturing enterprises, as well as three central vaccine research institutes. The Group is one of the first two human vaccine companies in the PRC that have been granted permission under the 14th Five-Year Plan of the PRC to build a bio-safety level 3 laboratory. Moreover, it is the world's largest manufacturer of hepatitis B vaccines and the world's second-largest manufacturer of rabies vaccines.

Company Overview

Company name	艾美疫苗股份有限公司
Name in English	AIM Vaccine Co., Ltd.
Stock code	06660.HK
Date of establishment	2011
Main business	The Company is principally engaged in the research and development, production, and sales of human vaccines. The Company's major products include Recombinant HBV Vaccine (Hansenula Polymorpha) and Freezedried Human Rabies Vaccine (Vero cell), among others.
Headquarters address	26/F, Building T6, Han's Plaza, 2 Ronghua South Road, Economic-Technological Development Area, Beijing
Number of employees	1,466
Operating revenue	RMB1.166 billion
Total assets	RMB6.544 billion

AIM Vaccine is a large privately owned vaccine group in the PRC with a full industry value chain. Our business covers the entire industry value chain from research and development to manufacturing and then commercialisation, achieving sales of vaccine products across the PRC's 31 provinces, autonomous regions and municipalities directly under the central government. AIM Vaccine is a vaccine enterprise with five validated human vaccine platform technologies, which provides the Group with robust assurance in terms of research and development speed and flexibility. During the reporting period, the Group had eight commercialised vaccines for six disease areas, as well as 20 innovative vaccine candidates under development for 12 disease areas. The products in production and under development covered all vaccine products ranked in the world's top ten (by global sales in 2020).

Through years of development, the Group has formed an inclusive and pioneering business model and corporate culture, enabling us to continuously expand and optimise our existing businesses. During the reporting period, the Group has four wholly-owned licensed vaccine manufacturing enterprises, including AIM Honesty, AIM Action, AIM Persistence, and AIM Rongyu. We held controlling interests in three research institutes, including AIM Explorer, a research and development centre established in 2018, which focuses on providing technical support for early-stage and cutting-edge research conducted by the R&D departments of our factories. In 2021, the Group acquired Liverna Therapeutics Inc, which was one of the three earliest enterprises in China to obtain clinical trial approval for an mRNA COVID-19 vaccine, and has proprietary mRNA manufacturing and drug delivery technology platforms.

Corporate Culture

AIM Vaccine has always upheld the mission of developing and manufacturing top quality vaccines to safeguard the health of the world, with the corporate vision to become a global leader in the vaccine industry. With innovation, honour, responsibility, dream, action, and persistence as core corporate values, we advocate an innovative corporate culture of inclusiveness, openness and empowerment, and strictly control the quality of vaccines.



Vision

To become a global leader in the vaccine industry



Mission

Developing and manufacturing top quality vaccines to safeguard the health of the world



Core values

Innovation, Honour, Responsibility, Dream, Action, Persistence

Development History

2011-2014
Initial Spark, Forging Ahead into New Frontiers

2011 The Company was established.

2012 The Company forged an open, collaborative, and empowering corporate culture featuring co-creation, win-win, and shared responsibility.

2013 The Company gradually built a network covering all 31 provinces, municipalities, and autonomous regions nationwide.

2014 The Company initiated the mission to develop and manufacture top quality vaccines to safeguard the health of the world and the vision to become the leader in the vaccine industry.

2015-2020
Integrated Expansion, Scaling New Heights

2015-2018 The Company integrated AIM Honesty, AIM Action, AIM Persistence, and AIM Rongyu.

2018-2019 The Company established AIM Explorer and put it into operation.

2020 The Company was restructured into a joint stock limited company.

2021-2025
Advancing R&D and Market Expansion in Parallel

2021 The Company integrated AIM Liverna and established AIM Innovator; obtained clinical trial approvals for the 23-valent Pneumonia Polysaccharide Vaccine and the Tetravalent Meningococcal Conjugate Vaccine.

2022 The Company was successfully listed on the Main Board of the Hong Kong Stock Exchange.

2023-2024 The Company opened a strategic partnership with the China Hepatitis Prevention and Control Foundation; multiple products achieved significant progress in clinical trials and production.

2025 The Company advanced the R&D of several core blockbuster products, featuring unique technological advantages and substantial market potential.

Major Honours and Social Recognition

Company Honours (Partial)

Awardee	Award	Issuing Organisation
AIM Vaccine	Excellence in Capital Markets Communication Award Excellence in Digital Investor Relations Award Excellence in Investor Relations Project Award	RoadshowChina
	Top 100 Chinese Pharmaceutical Innovative Enterprises List and Top 5 in the Nucleic Acid Track	E Healthcare Executive
	Top 50 Biologics R&D Strength in China	Yaozhi Pharmaceutical Intelligence Consulting
AIM Explorer	High and New Technology Enterprise	Science and Technology Commission of Shanghai Municipality Shanghai Municipal Finance Bureau/Shanghai Municipal Tax Service, State Taxation Administration
	Innovative Small and Medium-sized Enterprises (SMEs)	Shanghai Municipal Commission of Economy and Informatization
AIM Honesty	Liaoning Province Individual Champion of Manufacturing Industry	Department of Industry and Information Technology of Liaoning Province
	Top 100 Manufacturing Enterprises in Dalian	Dalian Enterprise Federation, Dalian Entrepreneurs Association
	High and New Technology Enterprise	Science and Technology Commission of Dalian Municipality/Dalian Municipal Finance Bureau/Dalian Municipal Tax Service, State Taxation Administration
AIM Persistence	High and New Technology Enterprise	Ningbo Science & Technology Bureau/Ningbo Municipal Finance Bureau/Ningbo Municipal Tax Service, State Taxation Administration
	Technology-based Small and Medium-sized Enterprises (SMEs)	Department of Science and Technology of Zhejiang Province
	Specialized, Refined, Differential, and innovative Small and Medium-Sized Enterprise (SMEs)	Ningbo Municipal Economy and Information Technology Bureau
AIM Rongyu	Specialized, Refined, Differential, and innovative Small and Medium-Sized Enterprise (SMEs)	Ningbo Municipal People' s Government
	High and New Technology Enterprise	Ningbo Science & Technology Bureau/Ningbo Municipal Finance Bureau/Ningbo Municipal Tax Service, State Taxation Administration
	Technology-based Small and Medium-sized Enterprises (SMEs)	Department of Science and Technology of Zhejiang Province
	Green Factory	Ningbo Municipal Beilun District Economic and Information Technology Bureau
AIM Action	High and New Technology Enterprise	Jiangsu Provincial Science and Technology Department/Department of Finance of Jiangsu Province/Jiangsu Provincial Tax Service, State Taxation Administration
	Specialized, Refined, Differential, and innovative Small and Medium-Sized Enterprise (SMEs)	Department of Industry and Information Technology of Jiangsu Province
AIM Liverna	High and New Technology Enterprise	Department of Science and Technology of Guangdong Province/Department of Finance of Guangdong Province/Guangdong Provincial Tax Service, State Taxation Administration
	Specialized, Refined, Differential, and innovative Small and Medium-Sized Enterprise (SMEs)	Guangdong Provincial Department of Industry and Information Technology

Industry Associations (Partial)

Participant	Associations (partial)	Position
AIM Vaccine	China Association for Vaccines (CAV)	Vice President
	CAV Supply Security Branch	Initiator
	CAV Supply Chain Branch	Member
	Developing Countries Vaccine Manufacturers Network (DCVMN)	Member
AIM Honesty	Dalian Pharmaceutical Profession Association	Chairman
	China Association for Vaccines (CAV)	Member
	Liaoning Pharmaceutical Profession Association	Member
	Liaoning Association for Biotechnology	Member
AIM Persistence	China Association for Vaccines (CAV)	Director
	Industry and Education Integration Community of National Biopharmaceutical Industry	Standing Director
	Ninghai Pharmaceutical Profession Association	Director
	Ningbo Pharmaceutical Association	Director
	Ninghai Association for Work Safety	Member
AIM Rongyu	China Association for Vaccines (CAV)	Director
	Zhejiang Pharmaceutical Association	Member
	Ningbo Pharmaceutical Profession Association	Member
	Ningbo Pharmaceutical Association	Member
	Zhejiang Association on Laboratory Animal Care	Member
AIM Action	China Association for Vaccines (CAV)	Member
AIM Liverna	China Association for Vaccines (CAV)	Member
	Hengqin Guangdong-Macao Deep Cooperation Zone Association for Big Health Biomedical Industry	Member
	Technology and Innovation Alliance for Research and Development of Vaccines for Emerging Infectious Diseases	Vice President

02 ESG Management

ESG Governance Structure

To ensure the effective operation of the ESG management system, AIM Vaccine established a three-tier ESG governance framework with clear authority and responsibilities and efficient coordination, deeply integrating the concept of sustainable development into our corporate strategy and decision-making processes, and forming a closed-loop management mechanism of "supervision by the Board of Directors-ESG working group coordination-collaboration among various functional departments/branches/subsidiaries" , thereby comprehensively ensuring the orderly advancement and implementation of environmental, social and governance (ESG)-related work.

We continued to explore ways to link ESG-related practices with remuneration. We gradually introduced ESG-related indicators, such as compliance and risk control, integrity and ethical conduct, and pharmaceutical safety, into senior management performance appraisals, and worked to link remuneration to ESG performance. In addition, the Company continues to strengthen its ESG capacity building by organizing senior management to participate in various ESG-related training sessions and exchanges initiated by external institutions, further deepening their understanding of ESG strategy and driving the continuous improvement of the Company' s ESG management system.

ESG Governance Structure and Work Responsibilities of AIM Vaccine

Supervisory and decision-making level

Board of Directors

It assumes ultimate responsibility for ESG management, exercise comprehensive oversight of ESG strategic planning, target setting and implementation progress, and makes decisions on and maintain control over major ESG matters.

Management level

ESG working group

As the coordinating and implementing body for ESG management, it is responsible for researching and formulating ESG policies and implementation plans, coordinating cross-departmental ESG work, and regularly reporting ESG management performance to the Board of Directors.

Execution level

Various functional departments/branches/subsidiaries

As the primary entities responsible for the implementation of ESG practices, they work in coordination with the ESG working group and are responsible for the execution and advancement of various ESG strategies, initiatives, and objectives within their department/unit.

Communication with Stakeholders

Effective stakeholder engagement is essential to strengthening ESG management and co-creating long-term value. AIM Vaccine clearly defines major stakeholders, including shareholders and investors, customers, employees, government and regulatory authorities, suppliers and partners, communities and the public, and experts and academics. We have established regular communication mechanisms to continuously monitor and respond to their needs and expectations.

The Group's ESG working group coordinates and aligns the relevant functional departments and, through diversified approaches combining online and offline channels, gathers input on the ESG topics of concern to stakeholders, identifies key demands, and incorporates these into the core basis for management and practical improvements, continuously optimising the ESG management system and effectively meeting stakeholders' expectations.

Topics of Concern to AIM Vaccine's Key Stakeholders and Communication Channels

Types of Key Stakeholders	Topics of Concern	Communication Channels
Shareholders and investors	• Corporate Governance • Protection of Investor Rights • Compliant Operations • Business Ethics	• General Meeting of Shareholders • Roadshows and communication meetings • Investor Open Day activities • Information disclosure
Customers	• R&D and Innovation • Intellectual Property Protection • Medical Research Ethics • Product Safety and Quality • Customer Service Management • Information Security and Privacy Protection	• Customer research • Thematic seminars • Customer visits
Employees	• Employee Recruitment and Rights • Human Capital Development • Work Safety	• Internal communication platform • Employee training • Trade union activities
Government and regulatory authorities	• Environmental Management • Resource Utilisation • Energy Management • Emissions Management • Response to Climate Change	• Institutional investigation • Policy implementation • Information disclosure • Official correspondence
Suppliers and partners	• Compliant Operations • Business Ethics • Supplier Management	• Exchanges and mutual visits • Industry forums • Supplier evaluation
Communities and the public	• Community Investment and Public Welfare • Access to Healthcare	• Volunteer services • Community activities • Public welfare promotion
Experts and scholars	• R&D and Innovation • Intellectual Property Protection	• Forum activities • Training exchange • Expert consultations

Analysis of Materiality Topics


To adequately address the challenges arising from changes in the internal and external environment, AIM Vaccine has actively carried out an ESG materiality topics assessment to enhance its ESG management standards. The Group conducted a materiality assessment from the environmental, social and governance perspectives, in accordance with Appendix C2, the *Environmental, Social and Governance Reporting Rules*, of the Hong Kong Stock Exchange's Listing Rules, and in conjunction with feedback from key stakeholders.

In accordance with the process of identifying, prioritising, reviewing and reporting materiality topics, the Group analysed the importance of each topic to stakeholders and its importance to the Group's business. Through departmental interviews, expert analysis and other approaches, the Group comprehensively determined its high-materiality topics, and made key disclosures and responses in this report.

Materiality Analysis Process for AIM Vaccine ESG Topics

Identification	• In accordance with the policy requirements of the *Environmental, Social and Governance Reporting Rules* issued by the Hong Kong Stock Exchange, and with reference to ESG management practices of leading peer companies, we identified 21 materiality topics, taking into account the Group's actual operational conditions.
Prioritisation	• Based on communication with stakeholders, and in combination with internal interviews and expert opinions, we conducted an analysis of ESG materiality topics, prioritised the topics, and identified those of high materiality as well as those of medium and low materiality.
Review and Reporting	• The Board of Directors reviews and confirms the material topics. For topics of high materiality, we provide focused disclosures in the ESG report.

2025 Materiality Topics Matrix of AIM Vaccine




03 Sound Governance for Steady Progress and Long-term Success

Corporate Governance

Governance Structure

By strictly complying with the requirements of laws, regulations, and documents including the *Company Law of the People's Republic of China*, HKEX's Listing Rules, HKEX's *Main Board Listing Rules*, the Hong Kong Companies Registry's *Companies Ordinance*, Hong Kong's *Securities and Futures Ordinance*, and the *Guidelines on Disclosure of Inside Information* issued by the Securities and Futures Commission of Hong Kong and in line with the Company's actual development needs, AIM Vaccine has formulated the *Articles of Association* and supporting governance documents, continuously improved its corporate governance system, ensured standardised and transparent operations, and effectively safeguarded the lawful rights and interests of shareholders and stakeholders.

AIM Vaccine Governance Structure



During the reporting period, AIM Vaccine convened a total of one general meeting of shareholders and six meetings of the Board of Directors. The committees under the Board of Directors held two Audit Committee meetings, two Compliance and Risk Control Committee meetings, one Nomination Committee meeting, one Remuneration and Appraisal Committee meeting, and one Strategy Committee meeting, respectively.

Board Diversity

As the Group's core decision-making body, the Board of Directors' professional capabilities and diversified structure are crucial to the Group's sustainable development. The Group's Board of Directors consists of nine members, including five executive directors, one non-executive director, and three independent non-executive directors The Board of Directors' members possess a balanced combination of knowledge and skills, covering key areas such as investment, business, media, finance, academia, and research and development, and have extensive practical experience in the healthcare and pharmaceutical industries, providing strong support for the Company's strategic decision-making.

The Group attaches importance to promote diversity within the Board of Directors. When selecting directors, it comprehensively considers a range of diverse factors, including gender, age, cultural and educational background, industry experience, technical capabilities, professional qualifications, knowledge reserves, and length of service. We prohibit any form of discrimination to ensure that the selection process is fair and impartial. The final appointment of the Board of Directors members of the Group is primarily based on the candidates' professional contributions and value that they can bring to the Board and the Group's development. The Board of Directors' Nomination Committee reviews and assesses its structure, size, and composition annually, and makes recommendations on any necessary adjustments to ensure the effective implementation of diversity policy.

Overview of Diversity and Independence of the Board of Directors of AIM Vaccine

Type of Director	Gender	Age	Cultural and Educational Background
• 5 executive directors • 1 non-executive director • 3 independent non-executive directors	• 8 men • 1 woman	• 3 persons aged 50–59 • 6 persons aged 60–69	• 5 PhDs • 3 Master's degree holders • 1 Bachelor's degree holder

Protection of Investor Rights

Information Disclosure

In terms of information disclosure, AIM Vaccine strictly complied with the requirements of laws, regulations, and documents including the *Securities and Futures Ordinance of Hong Kong* and the *Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited*, effectively fulfilled our information disclosure obligations, ensured that disclosed information was true, accurate, complete, and released in a fair manner, safeguarded the right of all shareholders to access information on an equal basis, and protected the legitimate rights and interests of the Company, shareholders, creditors, and other stakeholders.

During the reporting period, the Group released a total of 13 voluntary announcements on research and development and 38 other types of announcements through the designated channels of the Hong Kong Stock Exchange, disclosing a total of 51 announcements and related documents.

Investor Communication

In terms of investor communications, the Group regards investor engagement as a core lever for enhancing ESG transparency and communicating the value of sustainable development, and maintains efficient and in-depth interactions with the capital market through multiple channels. During the reporting period, the Group conducted more than one hundred online and offline engagement

activities through offline roadshows, telephone calls, video, livestreaming, reverse roadshows, and investor open days, among other formats. A total of seven securities analyst reports were issued, three investor open days were held online, and more than one hundred online and offline research activities were received, effectively reaching hundreds of investment institutions and deepening investors' understanding of our value creation and sustainable development ecosystem.

To enhance investor relations efficiency and the transparency of ESG information disclosure, the Group has actively advanced the digital transformation of investor relations (IR), establishing a comprehensive digital management system.

IR Digital Transformation Initiatives of AIM Vaccine

Build a diversified communication matrix	Leveraging our proprietary platforms such as the IR WeChat official account, IR video account, and IR WeChat groups, and in collaboration with third-party platforms such as RoadshowChina and Snowball as well as the PR team, we have established a widely covered content dissemination network, enabling ESG and business information to reach the market promptly and accurately at the earliest opportunity.
Optimise information disclosure tools	The IR official account supports one-click retrieval of announcement documents, automatic title recognition, and intelligent search for posts and research reports, significantly enhancing the convenience and efficiency of ESG and compliance information disclosure.
Upgrade the IR management system	The investor relations management system has already covered over 1,000 investors and provided precise profiling. We have conducted in-depth communications with more than 50 securities firms and over 100 professional analysts, and carried out at least one targeted ESG and business communication each quarter. Meanwhile, we have released updates on ESG progress and Company developments dynamically through the IR video account and official account, strengthening efficient engagement.
Implement a professional project-based management process	Taking the 2025 interim results announcement and presentation as an example, the team formed a dedicated project team in advance, developed a detailed timetable and division-of-responsibilities schedule, clarified the deliverables, responsible persons and reviewers, synchronised project progress on a daily basis, and ensured the professionalism and timeliness of ESG and performance information disclosure.

Compliant Operations

The Group strictly complied with the requirements of laws, regulations, and documents including the *Company Law of the People's Republic of China* and the *Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited*, and established a Compliance and Risk Control Committee, under which the Legal Affairs and Compliance Department and the Integrity and Audit Department were set up, thereby building a compliance risk control management structure with clear powers and responsibilities and efficient collaboration.

At the same time, the Group, in line with actual operational conditions, has formulated and continuously improved its compliance management system, detailed rules for risk prevention and control, and operating procedures. We have established a compliance management system covering the entire operational process, each business segment, and all subsidiaries, ensuring that compliance and risk control efforts are conducted with a legal basis and clear rules to follow, and effectively preventing various compliance risks in operations and management.

Compliance Management Structure of AIM Vaccine

Compliance and Risk Control Committee	• As the top-level decision-making and supervisory body for the Group's compliance management, responsible for providing professional recommendations on improving the compliance governance system and strengthening risk control, based on the Group's operational compliance status and risk prevention and control landscape.
Legal and Compliance Department Integrity and Audit Department	• As the core execution body of compliance management, responsible for organising and implementing various compliance management tasks. • It conducts regular annual compliance assessments of employees and business partners. For any instances identified during the assessments that do not meet the Company's compliance requirements, it takes corresponding rectification or disciplinary measures in accordance with applicable laws and regulations, thereby ensuring the effective implementation of compliance management.

For the handling of routine compliance incidents, the Group adhered to the principles of proactive investigation and open supervision. The Integrity and Audit Department set up a compliance and risk control whistle-blowing mailbox, providing an equally accessible supervision and reporting channel for all employees. The heads of the Group and each subsidiary may report compliance or risk issues encountered during operations. Upon review by the Legal Affairs and Compliance Department and issuance of written opinions, a formal proposal will be submitted to the Compliance and Risk Control Committee. The Compliance and Risk Control Committee meetings review and assess the reports provided by the Legal and Compliance Department, and submits the relevant written resolution materials to the Board of Directors for discussion, thereby establishing a top-down, closed-loop and efficient compliance and risk control management mechanism.

The Group attaches great importance to fostering a culture of compliance. We advocate that all employees and business partners operate in accordance with laws and regulations and conduct business with integrity. We maintain a zero-tolerance approach towards illegal and non-compliant conduct and breaches of professional ethics, in particular bribery and corruption, and unfair competition. To ensure that this culture of compliance is embedded into day-to-day workflows, the Group regularly conducts internal compliance inspections and reviews, adopts robust accountability mechanisms internally, and carries out regular compliance-specific training, thereby strengthening all employees' compliance awareness and behavioural baseline.

Business Ethics

The Group has always adhered to the bottom line of law and ethics, strictly complying with the *Anti-Unfair Competition Law of the People's Republic of China, the Anti-Monopoly Law of the People's Republic of China, the Anti-Money Laundering Law of the People's Republic of China*, the *Oversight Law of the People's Republic of China* and other laws and regulations, upholding high-standard business ethics and resolutely resisting any form of corruption, commercial bribery, unfair competition, and money laundering.

The Group has established management policies such as *Anti-Fraud Management Regulations, Interim Measures for Internal Audit of Management Personnel Upon Departure (Resignation)*, and the *Anti-Corruption and Anti-Bribery Management Measures* to strengthen anti-corruption ideological development. The Group is committed to building an honest, incorruptible, and compliant operating environment, ensuring that all business activities are carried out in accordance with laws and regulations. The Group designates the Board of Directors and the Audit Committee as the decision-making level, responsible for guiding and overseeing the implementation of anti-fraud efforts. Management is responsible for establishing, improving, and effectively implementing anti-fraud procedures and controls, including fraud risk assessment and fraud prevention. Business departments, the Legal and Compliance Department, and the Integrity and Audit Department together form the "three lines of defense" and are responsible for carrying out specific anti-fraud measures.

During the reporting period, the Group was not involved in any commercial ethics-related litigation cases such as corruption, bribery, fraud, extortion, or money laundering.

Three Lines of Defence Process of AIM Vaccine

First Line of Defense	Second Line of Defense	Third Line of Defense
All business departments: compliance with policies and internal supervision	Legal and Compliance Department: Routine review and dispute resolution	Integrity and Audit Department: Special inspections and case investigation and handling

The Company adopted a zero-tolerance approach to any form of misconduct, such as corruption and bribery, established and improved whistleblowing mechanisms and an end-to-end supervision system, and deeply integrated high standards of business ethics and codes of conduct into its daily operations, ensuring that all employees consistently uphold the basic principles of lawfulness, compliance, and integrity.

AIM Vaccine Whistleblowing Mechanism

Ensure reporting channels remain open	• A complaints and reporting email address has been established, encouraging stakeholders such as employees, suppliers and business partners to actively conduct oversight and report concerns.
Strengthen whistleblower protection	• A dedicated person was assigned to manage whistleblowing information, which was stored confidentially. Disclosing the whistleblower's identity or the content of the report was strictly prohibited.
Standardise whistleblowing case handling process	• The Integrity and Audit Department received reports, conducted investigations, reported findings, and put forward recommendations, and was subject to the supervision of the Audit Committee and the Board of Directors. • Report leads were handled by designated personnel. During the investigation and verification stage, confidentiality was strictly maintained. Verified violations were dealt with seriously in accordance with laws and regulations, ensuring that violations were promptly rectified.

During the reporting period, the Group's Integrity and Audit Department carried out multiple special initiatives focusing on advancing special audits on procurement, special business and supply chain audits, and integrity training and awareness enhancement.

2025 Anti-Corruption Initiatives of AIM Vaccine

Advancement of Special Procurement Audits

- We have continued to advance special procurement audits for subsidiaries, steadily progressing towards the goal of achieving full coverage of procurement audits across all subsidiaries by 2026.
- In 2025, we completed special procurement audits for two subsidiaries. For one of the subsidiaries, while conducting the procurement audit, we simultaneously carried out a comprehensive audit of its operations and management, in order to thoroughly identify compliance risks in both procurement and operational processes.

Special Business and Supply Chain Audits

- We selected specific sales personnel to conduct specialised business audits, and jointly advanced the relevant projects in collaboration with external professional accounting firms.
- In cooperation with external third-party audit institutions, we conducted audits on suppliers' business ethics practices, strengthened integrity and compliance management across the supply chain, and reinforced a robust integrity and compliance framework throughout the entire value chain.

Integrity Training and Awareness Enhancement

- We provided integrity and compliance training for newly recruited employees and, at the invitation of subsidiaries, delivered specialised anti-fraud training for middle management and above. These initiatives enhanced employees' awareness of integrity and compliance.
- We conducted regular company-wide training on anti-corruption, anti-fraud, anti-monopoly, and fair competition, and incorporated compliance training into performance evaluations. This strengthened compliance awareness among all employees and promoted the deep integration of compliance principles into daily operations.

04 Innovation-Led, R&D-Driven


R&D and Innovation

R&D Mechanism Development

Driven by R&D and innovation, the Group, guided by corporate vision to become a global leader in the vaccine industry, is committed to building a globally competitive vaccine research and development system. The Group has established the *Project R&D Management Procedures* to implement standardised and professional end-to-end management of research and development projects, ensuring that projects are advanced rigorously and efficiently.

The Group established the Global R&D Management Centre, which is responsible for coordinating and overseeing R&D activities and managing all R&D projects across the Group in a unified manner. At the same time, an External Scientific Advisory Committee was established. The committee is composed of outstanding scientists from the vaccine industry in China and is primarily responsible for providing research and development support, thereby safeguarding the efficiency of vaccine research and development. The Group's R&D team, as the core internal R&D organisation, is composed of R&D personnel from three vaccine research institutions, namely AIM Explorer, AIM Innovator and AIM Leader, and four wholly-owned vaccine manufacturing companies, namely AIM Honesty, AIM Action, AIM Rongyu and AIM Persistence. The three research institutions and the four licensed vaccine manufacturing enterprises each have their own research strengths, collaborating on R&D and manufacturing to jointly advance the development of new vaccine product pipelines.

R&D Management Structure of AIM Vaccine



To enhance the relevance and precision of research and development, the Group is accelerating the in-depth integration of artificial intelligence technologies into vaccine research and development. At this stage, we are applying AI to support antigen structure prediction, mRNA sequence design and optimisation, and are exploring the application of AI in screening parameters for process development. In the future, we plan to further deepen the application of AI across all stages of research and development, particularly by expanding into areas such as clinical trial data analysis and immunogenicity prediction, in order to enhance research and development efficiency and the success rate.

Building on our continuous accumulation and practice in research, development and innovation, during the reporting period, AIM Explorer and AIM Action successfully obtained High and New Technology Enterprise certification, marking further recognition of the Company's achievements in technology research and development and innovative application.

High and New Technology Enterprise Certification Status of AIM Vaccine

Company Name	High and New Technology Enterprise Certification
AIM Explorer	Obtained certification, and it remained valid as of the end of the reporting period
AIM Liverna	Obtained certification, and it remained valid as of the end of the reporting period
AIM Action	Obtained certification, and it remained valid as of the end of the reporting period
AIM Honesty	Obtained certification, and it remained valid as of the end of the reporting period
AIM Rongyu	Obtained certification, and it remained valid as of the end of the reporting period
AIM Persistence	Obtained certification, and it remained valid as of the end of the reporting period

The Group's R&D and innovation objective management is led and coordinated by the Global R&D Management Center, in collaboration with the R&D teams of its subsidiaries, the Clinical Medicine Department, the Registration and Filing Department, and various functional departments. Together, they have established a full-process, cross-departmental R&D project management system to provide lifecycle management and comprehensive support for R&D projects across all departments and subsidiaries, ensuring that R&D activities are advanced efficiently, in a standardized and orderly manner, thereby supporting the implementation of the Group's innovation strategy and enhancing its core competitiveness.

AIM Vaccine's Innovative R&D Porcess

Project Initiation Review

- Formulate clear R&D and innovation plans and objectives in alignment with strategic development goals.
- The review covers four key aspects "forward-looking R&D, budgeting and planning, risk management, and decision-making basis" to ensure scientific decision-making and strict control over R&D risks.

Project Implementation

- Establish a project implementation system featuring "clear division of responsibilities, efficient collaboration, and end-to-end control," with a focus on key areas such as progress management, regulatory registration, and clinical trials, so as to ensure the efficient execution of R&D projects.

Review and Evaluation

- Develop project assessment plans, set evaluation objectives, and organize their implementation. Regular assessments of ongoing projects are conducted, with a focus on comprehensively evaluating the achievement of key milestone targets and implementation timeliness.
- For targets that fall short of expectations, root causes are analyzed in a timely manner and corrective measures are developed to ensure closed-loop resolution of issues.

R&D Capability Development

To enhance the team's R&D and innovation capabilities, the Group has provided department-level and Company-level R&D training, and regularly organised technical sharing sessions, literature seminars, and R&D and innovation topic-specific training. During the reporting period, the Group organised Company-wide topic-specific training on subjects such as on-site inspection for development and manufacturing, microbiological knowledge and contamination control, and the identification of critical quality attributes and critical process parameters, to ensure the deep integration of R&D knowledge and practice and provide a solid safeguard for the sustainability of innovation.

To stimulate employees' initiative and creativity, the Group has established an intellectual property award and remuneration management mechanism, providing reward funds for inventors and designers to recognise their contributions to the creation and protection of intellectual property, incentivise employees' innovative spirit. This will provide talent support for the Company's long-term development.

Innovative R&D products

In terms of R&D of innovative products, guided by market demand, the Group's R&D teams have jointly developed and manufactured new vaccine varieties through cross-functional and cross-laboratory research and development approaches.

The Group has all five validated human vaccine technology platforms worldwide, ensuring the Group's research and development speed and flexibility. Under each technology platform, AIM Vaccine had at least one commercialised vaccine or one vaccine candidate under preclinical research.

R&D Pipeline Diagram of AIM Vaccine

Technology Platform	Indication	Vaccine Candidate	In-house R&D/Joint Development	Preclinical	CTA	Phase I	Phase II	Phase III	NDA & NDA Approval
Viral Vaccine	Rabies	Iterative Serum-free Rabies Vaccine	In-house R&D	Application for marketing registration has been submitted					
		Iterative Novel-process High-potency Human Diploid Rabies Vaccine	In-house R&D	Phase III Clinical Trial has Completed on-site work					
	HFMD	EV71-CA16 Bivalent HFMD Vaccine(HCD)	In-house R&D	Phase I Clinical Trial is Ongoing					
	Influenza	Quadrivalent Influenza Virus Vaccine (MDCK Cells)	In-house R&D	Clinical approval has been obtained					
Bacterial vaccine	Pneumonia Disease	20-valent Pneumococcal Conjugate Vaccine(PCV20)	In-house R&D	Clinical approval has been obtained					
		24-valent Pneumococcal Conjugate Vaccine(PCV24)	In-house R&D	Preclinical Research Completed					
		13-valent Pneumococcal Conjugate Vaccine(PCV13)	In-house R&D	Undergoing Supplementary Studies as Required by the CDE					
		23-valent Pneumococcal Polysaccharide Vaccine (PPSV23)	In-house R&D	Phase III Clinical Data Unblinding					
	Meningococcal Disease	Tetravalent Meningococcal Conjugate Vaccine(MCV4)	In-house R&D	Phase II Clinical Trial is Ongoing					
		Hexavalent Meningococcal Vaccine	In-house R&D	Preclinical Research					
	Group B Strep Disease	Hexavalent Group B Streptococcus Polysaccharide Conjugate Vaccine	In-house R&D	Preclinical Research					
	Tetanus	Absorbed Tetanus Vaccine	In-house R&D	Phase I Clinical Trial is Ongoing					
	Hib Infection	Haemophilus Influenzae Type B (Hib) Conjugate Vaccine	In-house R&D	Clinical approval has been obtained					
Combination vaccine	DTP	Diphtheria, Tetanus and Pertussis and Haemophilus Influenzae Type B and Quadrivalent Meningococcal Conjugate (DTcP-Hib-Mcv4) Combination Vaccine	In-house R&D	Preclinical Research					
		Diphtheria, Tetanus and Acellular Pertussis (Components) Combined Vaccine (DTcP)	In-house R&D	Preclinical Research					
mRNA vaccine	Rabies	Iterative mRNA Rabies Vaccine	In-house R&D	Pre-application for Clincal Trials					
	Shingles/ Herpes Zoster	mRNA Shingles/Herpes Zoster Vaccine	In-house R&D	Clinical approval has been obtained (China and the United States)					
	Respiratory Syncytial Virus Infection	mRNA Respiratory Syncytial Virus Vaccine (RSV)	In-house R&D	Clinical approval has been obtained (China and the United States)					
	Influenza	mRNA Influenza Vaccine	In-house R&D	Preclinical Research					
Genetically Engineered Vaccine	Meningococcal Disease	Recombinant Group B Meningococcal Vaccine	In-house R&D	Preclinical Research					

viral vaccine platform | bacterial vaccine platform | mRNA vaccine platform | genetically engineered vaccine platform | combination vaccine platform

The Group continued to optimise the allocation of R&D resources to ensure that our R&D outcomes effectively met market needs. As of the end of the reporting period, the Group had 20 pipeline vaccines in 12 disease areas, had obtained 24 clinical approvals, and conducted 24 clinical trials. In 2025, in terms of marketing registration and clinical approvals, the Group obtained seven clinical approvals, and one products (Iterative Serum-free Rabies Vaccine) had their marketing registration accepted by the Center for Drug Evaluation (CDE) of the National Medical Products Administration. One product (Iterative 13-valent Pneumonia

Conjugate Vaccine) is undergoing supplementary studies as required by the CDE. Two mRNA products (Iterative mRNA Shingles Vaccine and Iterative mRNA RSV Vaccine) were approved to conduct clinical trials in both China and the United States. In terms of clinical trials, the Group's newly developed Iterative-process High-potency Human Diploid Cell Rabies Vaccine completed the Phase III clinical trial, and subsequent work will be progressively advanced to the marketing registration stage; the 23-valent Pneumonia Polysaccharide Vaccine has completed unblinding, and the clinical summary report has been obtained. The Group has achieved fruitful research and development results, further demonstrating the Group's leading position in the field of vaccine research and development.

During the reporting period, the Group focused on the research and development of three innovative products with significant market potential and unique technological advantages, supporting public infectious disease prevention and control and enhancing public health standards; Meanwhile, we were also advancing the research and development of novel dosage forms and administration routes such as the intranasal influenza vaccine, enriching vaccine delivery pathways, further broadening the boundaries of vaccine applications and enhancing inclusive value.

Introduction to AIM Vaccine's Innovative Products for 2025

Iterative Serum-free Rabies Vaccine

- Free of animal serum; significantly improved safety, reducing the likelihood of adverse reactions.
- As at the end of the reporting period, no serum-free rabies vaccine had been approved for marketing globally. This product will help fill a market gap and improve public health standards.
- A world-leading matrix of iterative rabies vaccines.

Iterative High-potency Human Diploid Cell Rabies Vaccine

- Took the lead in overcoming the technical bottleneck of low viral titres in traditional processes, resolved the challenge of high-titre virus culture in large-scale bioreactors, and optimised the purification process, significantly improving product quality and safety.
- Overcame technological barriers and reshaped the technological landscape of rabies vaccines.

Iterative 20-valent Pneumonia Conjugate Vaccine

- Seven additional serotypes were added on the basis of the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine, comprising a total of 20 currently predominant pneumococcal serotypes.
- Our independently developed polysaccharide-protein conjugation technology resolved the dual-high dilemma of process complexity and quality control density.
- Built a broad-spectrum vaccine barrier, breaking Pfizer's exclusive monopoly in the 20-valent pneumonia vaccine market.

mRNA RSV Vaccine

- Humoral and cellular immunity in animal studies were both significantly higher than those of international benchmark products, and the mRNA technology platform has gained international recognition.
- Directly competited with Pfizer/GSK/Moderna, the three giants, in RSV.
- Achieved 100% domestic production across the entire mRNA industry chain.

mRNA Shingles Vaccine

- The product's immunogenicity exceeds that of leading international vaccine companies.
- It is expected to become a safer and more effective domestic alternative.

Intellectual Property Protection

By strictly complying with laws and regulations including the *Patent Law of the People's Republic of China, the Trademark Law of the People's Republic of China* and the *Copyright Law of the People's Republic of China*, the Group has formulated internal management policies such as the *Intellectual Property Management Policy, Patent Management Policy and Trademark Management Policy*, refined intellectual property management procedures, and promoted the Group and its employees to continuously carry out independent innovation.

The Group has established a dedicated intellectual property management department responsible for intellectual property planning, implementation, and supervision.

Intellectual Property Protection Measures and Achievements of AIM Vaccine

Prior to product project initiation

- Conducted a systematic review of patent applications and legal status relating to products and key technologies, comprehensively clarifying our own rights boundaries and potential risks, and avoiding losses arising from infringement.
- Conducted patent search and analysis to provide a basis for R&D decision-making and intellectual property risk management.

Upon product project initiation

- Planned scientifically and applied for patent protection in key technologies and innovative fields, thereby enhancing the Group's intellectual property protection standards.
- Engaged a third party to conduct patent non-infringement searches and issued patent non-infringement reports, thereby strengthening the Group's proactive risk management capabilities.

Routine management

- Track industry patent developments to enable the Group to avoid infringement risks prior to research and development, and build a robust patent protection network around our own technologies.
- Conduct intellectual property protection communications and training for employees to enhance intellectual property protection awareness and prevent behaviours such as infringement and leakage of confidential information.

During the reporting period, the Group continued to strengthen intellectual property protection, with 14 new patent applications filed and 31 new patents granted. As at the end of the reporting period, the Group had a total of 189 valid patents. During the reporting period, the Group did not receive any penalties from the competent authorities for intellectual property infringement, nor were there any lawsuits or major administrative penalties arising from the Company's unfair competition practices.

Medical Research Ethics

Clinical Trial Management

The Group strictly complied with the requirements of laws, regulations and documents including the *Drug Administration Law of the People's Republic of China*, the *Regulations for Implementing the Drug Administration Law of the People's Republic of China*, and *Good Clinical Practice (GCP)*. We established a clinical trial quality management system (cQMS), formulated clinical standard operating procedures (SOPs) and a series of internal management policies, covering clinical standard operating procedure documents and governance charters, involving 10 core areas including job responsibilities, staff training, supplier management, project management, risk management, and quality control. During the reporting period, the Group continued to update and maintain SOPs and clinical trial quality system documentation. A total of 40 SOPs and 122 appendices were updated to further standardise end-to-end clinical trial management processes, ensure clinical trial quality, and facilitate progress in clinical development.

Meanwhile, based on the cQMS quality management system, the Group continuously optimised the digital development of clinical trials. Through the vaccine clinical trial process management system, the interactive web response system (IWRS), the electronic data capture (EDC) system for clinical trials, and others, we scientifically tracked the progress of clinical trials and enhanced data security and reliability.

Introduction to AIM Vaccine Clinical Trial Management Systems

System Name	System Overview
Vaccine clinical trial process management system	It achieves end-to-end management of trial participant recruitment, trial progress, and data; monitors trial progress in real time and promptly resolves issues, ensuring the smooth conduct of clinical trials.
EDC system	It established an efficient data collection and transmission platform to automatically collect, integrate, and transmit clinical data. It enhances the efficiency and accuracy of data acquisition while ensuring data integrity, providing a reliable basis for subsequent scientific analysis.
New drug intelligence centre	It tracks and analyses new drug research and development dynamics in real time, integrating drug information, patent data and market intelligence, to provide information support for formulating scientific clinical trial strategies and enhancing research and development efficiency.
IWRS system	It is responsible for the management of investigational products and the randomisation of participants, ensuring the fairness and randomness of the allocation process and enhancing the scientific rigour of trial design.
eSign electronic signature system	It improves the efficiency and accuracy of signatures by replacing traditional paper-based signing with an electronic signing process, supports rapid document approval and filing, and ensures the smooth advancement of clinical trial processes.
Lenovo Filez cloud storage	As a core document management platform, it provides secure and efficient capabilities for file storage, sharing, version control, and access management. While enhancing operational efficiency, it also ensures orderly and secure document management.

In addition, the Group established internal and external clinical trial training systems and adopted diversified training strategies to enhance employees' accumulation of clinical trial knowledge and develop high-calibre professionals. During the reporting period, the Group conducted a total of three clinical trial-related training sessions, providing training to 67 participants in total.

AIM Vaccine Clinical Training Measures

Internal training

Job training

Provide customised development plans for new employees. Require personnel taking up their posts to attend GCP training and obtain qualification certificates. Conduct online and offline training assessments. Review and summarise the training.

External training

Training courses

Introduce external professional courses covering clinical trial methodologies, data analysis, and ethical regulations, thereby enhancing employees' professional knowledge and skills.

Training activities

Regularly organise employees to participate in industry seminars and professional forums, promoting exchanges with experts and peers in the field, and enabling us to keep abreast of scientific research developments and cutting-edge technological advances.

Training platform

Establish an integrated online learning platform, consolidating extensive learning resources, regularly updating professional courses, broadening employees' industry horizons, and systematically enhancing clinical professional competence.

Protection of Trial Participants' Rights and Interests

The Group placed participants' safety and rights and interests at the core. By establishing a subject rights and interests protection system with policies as the guiding framework, training as the foundation, technology as the shield, and safeguards as the cornerstone, we continuously optimised measures to protect participants' rights and interests and adhered firmly to the ethical baseline for research and development.

The Group fully considered ethical factors in clinical trials and commissioned compliant institutions such as hospitals to conduct clinical studies on participants. All clinical research institutions had ethics committees in place. As the sponsor, the Group strictly submitted to the ethics committees of relevant institutions the documents required for ethics review in accordance with regulatory requirements, such as the clinical trial protocol, investigator' s brochure, informed consent form, etc. The ethics committee fulfilled its review responsibilities, conducting a comprehensive and rigorous ethical review of the submitted materials to ensure that the clinical research process complied with medical ethical standards and effectively safeguarded the legitimate rights and interests of each trial participant.

The Group strictly complied with international ethical guidelines such as *World Medical Association' s Declaration of Helsinki* and the requirements of documents including *Good Clinical Practice (GCP) and Opinions on Strengthening the Governance of Science and Technology Ethics*, established a clinical research ethics governance framework centred on the cQMS system, developed SOP documents such as *Standard Operating Procedures for the Preparation and Submission of Ethics Materials* and *Standard Operating Procedures for Protocol Drafting and Revision*, and regularly reviewed and revised them to standardise ethics review applications, information submission, process oversight, and the scientific rigour of clinical trial protocols, ensuring the ethical compliance of clinical trials. At the same time, the Group adhered to scientific ethical standards and adopted multiple measures at the early, middle, and late stages of clinical trials to advance, to a high standard, the practice of protecting the rights and interests of participants.

Protection Measures for the Rights and Interests of AIM Vaccine Participants

Dimension		Management Measures
Protection of basic rights and interests	Protection of autonomy and the right to know	• Researchers fully informed participants of key factors such as the purpose, content, risks, expected benefits of the clinical trials, and the possibility of no benefit. Participants could participate voluntarily, thereby safeguarding their autonomy. • Developed the *Standard Operating Procedures for the Drafting and Revision of Informed Consent Forms* to standardise the required content elements of informed consent forms, special protection procedures for vulnerable groups participating in research, etc., ensuring that researchers explain research information fully and clearly to prospective participants. Participants voluntarily signed the Ethics Committee-approved Informed Consent Form, thereby safeguarding their right to be informed.
	Privacy protection	• Developed the *Standard Operating Procedures (SOP) for Privacy Protection of Research Participants*, specifying full-process protective measures and technical requirements for the collection, storage, use, transfer, and destruction of participants' personal information, safeguarding privacy rights and interests. • Used study codes to replace participants' identifying information, reducing the risk of participants' privacy exposure. • All clinical trial projects use certified encrypted electronic data capture systems and deploy data masking and anonymisation tools; implement strict hierarchical access control and access log tracking for personnel who come into contact with participants' information to ensure data traceability.
Risk control measures	Clinical risk control	• Monitor and provide early warnings of safety signals during clinical trials, develop an emergency response plan for serious adverse events (SAEs), and issue risk alerts. • Establish a medical emergency green channel at trial sites, and deploy professional medical staff and equipment to ensure timely medical treatment for participants.
	Guarantee of compensation for rights and interests	• Uniformly purchased Clinical Trial Liability Insurance for all participants in the Group's clinical trials, covering medical expenses and reasonable compensation for trial-related injuries. The claims process was clearly defined, and this clause was incorporated into the informed consent form. • In 2025, 100% of newly enrolled participants were covered by clinical trial insurance. Established a fast-track claims channel to provide effective protection for participants and ensured that subjects receive the maximum possible compensation.
	Ethics capacity building	• At least one clinical trial ethics-related SOP training session for all staff was organised each year, and induction training for new employees was conducted on an ongoing basis. The training content covered SOP learning across all modules of the department, including the clinical operations module, medical module, data management module, and project management module, among others.

Animal Welfare

The Group strictly complied with the *Regulations of the People's Republic of China on the Administration of Laboratory Animals* and the *Guiding Opinions on Treating Laboratory Animals Well* and other laws, regulations, and document requirements, and formulated the *Laboratory Animal Welfare and Ethics Review Management* SOP to standardise laboratory animal management and safeguard laboratory animal welfare.

The Group followed the 3R principles of Reduction, Replacement, Refinement for animal ethics to safeguard the welfare of laboratory animals through the Five Freedoms, namely, freedom from hunger and thirst, freedom from discomfort, freedom from pain, injury and disease, freedom to express normal behaviour, and freedom from fear and distress.

AIM Vaccine Measures to Safeguard Animal Welfare



Animal welfare safeguards

- AIM Rongyu fed laboratory animals with full-price nutritious feed and provided sufficient drinking water to ensure that laboratory animals did not suffer from hunger or thirst.
- AIM Honesty strictly implemented industry standards for the feeding, injection, anaesthesia, euthanasia, and other practices involving laboratory animals, treated animals well, and reduced suffering caused by pain at the time of death of laboratory animals.



Improvement of the breeding environment

- AIM Rongyu provides clean and dry bedding, ensuring that laboratory animals have sufficient and comfortable living space.
- AIM Rongyu simulates a natural day-night light and dark environment to enhance the living comfort of laboratory animals.



Optimisation of scientific experiments

- AIM Action complies with the principles of laboratory animal protection, animal welfare, ethics, and comprehensive scientific evaluation, and developed relevant SOPs to standardise laboratory animal management.
- Prior to conducting animal testing, AIM Action reviews the necessity of animal testing and stops unnecessary animal testing or animal testing with no social value.
- AIM Action has optimised animal testing protocols, encouraged the use of alternatives to animal testing, and reduced the number of animals used unnecessarily.
- AIM Action has improved experimental techniques to avoid or alleviate pain and distress to animals.

05 Quality First, Striving for Excellence

Product Safety and Quality

Product Quality Management

AIM Vaccine has always upheld the mission of developing and manufacturing top quality vaccines to safeguard the health of the world, adhered to the quality policy of "Quality First, Customer Satisfaction, Continuous Improvement", placed product quality management at the core, strictly controlled vaccine quality control and management, and ensured product safety.

Quality Management System Development

The Group strictly complied with the requirements of laws, regulations, and documents including the *Drug Administration Law of the People's Republic of China*, the *Vaccine Administration Law of the People's Republic of China*, *Good Manufacturing Practice for Pharmaceutical Products* (GMP), and *Measures for the Supervision and Administration of Drug Production*, and formulated internal policies including the Quality Management Manual, *Management Procedures for Production Sites*, and *Management Procedures for Annual Product Quality Review*. These covered aspects such as quality strategy, quality control, quality assurance, and quality improvement, and stipulated requirements for trend analysis of product quality and the preparation of annual product quality reviews. These required annual trend analysis and review audits of the quality of marketed products to confirm the stability and reliability of the product manufacturing process, and to formulate, as necessary, subsequent improvement directions in product and quality management.

The Group has established a comprehensive quality management system and set up a Group Quality Management Department responsible for supervising and guiding quality management of its subordinate manufacturing enterprises. Each manufacturing enterprise has established an internal Quality Assurance Department (QA) and Quality Control Department (QC), responsible for quality assurance and quality control of vaccine products. We have progressively developed a new quality management framework featuring prevention as the priority and systematic control, ensuring the safe and efficient production of vaccine products and safeguarding quality compliance and controllability.

AIM Vaccine Quality Management Measures

Quality system optimisation	• Established a Contamination Control Strategy (CCS) management system, developed *Contamination Control Strategy Management Procedures*, identified and assessed potential contamination risks throughout the entire production process, and prioritised advancing contamination prevention and control management, so as to ensure effective contamination control throughout the entire product production process and safeguard product quality.
Quality compliance management	• Conducted a gap analysis and benchmarking study against the new edition of *Chinese Pharmacopoeia*. Completed supplementary studies/validation based on the identified gaps and upgraded the relevant supporting documents, ensuring the smooth implementation of the new edition of the Pharmacopoeia.
Quality training enhancement	• On the basis of systematically providing routine quality training for all quality-related personnel, the Group also, guided by the requirements of regulations and guidelines, focused on delivering training on key digitalised systems to ensure their use, operation and maintenance ran smoothly and remained quality-compliant. During the reporting period, the Group did not identify any material deficiencies related to computerised systems. • The Group tracked in real time the release of industry regulations and guidelines. By establishing a training feedback mechanism and delivering training on the latest regulations, the Group achieved dynamic GMP management.
Quality culture development	• The Group actively conducted the communication and implementation of quality-related regulations, with a focus on enhancing employees' awareness of quality compliance. Through the development of a quality culture, we put into practice the Group's philosophy of "quality first."

Production Quality Management

To ensure quality control throughout the entire vaccine production process, the Group, in accordance with GMP, *Chinese Pharmacopoeia* and the Company's registration standards, strictly controlled the quality of materials, intermediates and finished products, as well as the production process, during the manufacturing stage. We established a quality management system covering the full product life cycle, and continuously and steadily produced vaccine products that met the required standards.

Production Quality Management Measures of AIM Vaccine

Policy development

- Developed SOP guidance documents such as *Management Procedures for Personnel Behaviour Standards in Clean Areas of the Production Department* to standardise production operations, reduced quality risks arising from operational errors, and ensured product quality.
- Based on the 2025 edition of the *Chinese Pharmacopoeia*, conducted item-by-item benchmarking assessments of risks throughout the entire pharmaceutical manufacturing process, and developed documents such as *Contamination Control Strategy (CCS) for the Production of Recombinant HBV Vaccine* to ensure compliance of the production environment.

Environmental control

- In compliance with the requirements of laws and regulations for ensuring sterility in production, developed the *SOP for Environmental Monitoring During the Production Process* and implemented sterility control measures for the production environment to ensure sterility in pharmaceutical manufacturing.

Production site management

- Built vaccine production workshops that comply with GMP standards to ensure ongoing compliance in relation to plant layout, maintenance of the clean production environment, and management of production facilities and equipment. In 2025, four manufacturing enterprises under the Group underwent more than ten GMP compliance and quality inspections by the national and other drug regulatory authorities at all levels, all of which were passed successfully. In addition, the Group's Honesty also obtained ISO 9001 quality management system certification.

Information management

- Fully leveraged electronic information systems for vaccines, such as LIMS, MES, and SCADA, to collect and record product manufacturing and quality data. This ensures the reliability and traceability of product data, reduces quality risks in production, and enhances production efficiency.

During the reporting period, the Group's quality management system received widespread recognition from domestic pharmaceutical regulatory authorities. Our four production subsidiaries all successfully passed GMP compliance inspections conducted at national and local levels, and production operations proceeded smoothly. The Group's four products, namely hepatitis A, hepatitis B, rabies and meningococcal, produced a total of 230 batches over the year and completed testing. The in-house testing pass rate was 100%. A total of 223 batches received approved lot release, with a pass rate of 100%. The marketed products demonstrated good safety, and no new safety risks were identified. All four enterprises passed special quality inspections and pharmacovigilance inspections conducted by regulatory authorities at all levels. Product quality remained continuously stable, and the production quality management system operated normally and improved steadily.

Product Quality Control

Based on the *Chinese Pharmacopoeia* and the Group's registered product specifications, the Group exercises strict quality control over raw materials and excipients, packaging materials, intermediates, and finished products to ensure a stable supply of high-quality vaccines that meet applicable standards.

Product Quality Control Measures of AIM Vaccine

Materials Management

- Established a routine inspection mechanism for the receipt acceptance of raw materials, excipients, and packaging materials.
- Conducted adventitious agent testing on all animal-derived raw materials and excipients.
- For all excipients, in addition to testing items required under the *Chinese Pharmacopoeia*, the Group also ensured that endotoxin and microbial limit tests were conducted.
- Conducted testing on critical ancillary materials used in production and materials used for inspection, further strengthening material quality control.
- Strictly implemented technical inspection sampling procedures for all packaging materials and conducted sampling inspections in accordance with the Acceptance Quality Limit (AQL), thereby achieving comprehensive control to high standards.

Management of Intermediate Products and Finished Prodcuts

- Strictly conducted testing in accordance with the *Chinese Pharmacopoeia* and the Group's registered product specifications and carried out stability studies are required.

Information quality management

The Group attaches great importance to the development of its digitalisation system, applying information systems to key quality-related processes such as production management, quality inspection, and product safety management. This enabled automated collection and real-time monitoring of key parameters, significantly improving inter-batch consistency and controllability of product processes, effectively reducing the risk of human operational errors, and safeguarding the stability and reliability of product quality. During the reporting period, based on our existing foundation, the Group continued to deepen system upgrades and functional expansion. Supporting SCADA, MES, LIMS and other digitalisation systems were newly established for new products such as the 13-valent pneumococcal conjugate vaccine and the serum-free rabies vaccine that are intended for marketing registration application, and system validation and go-live operation were completed. The Group's information development helped optimise quality data management, ensure data integrity, traceability and compliance, and continuously enhance our ability to identify and control quality risks, providing solid digital support for quality management across the product life cycle and compliant operations management.

Introduction to AIM Vaccine's Quality Management Information System

Data Acquisition and Monitoring System (SCADA)

Used for the collection, storage and management of data for key production-related facilities such as pharmaceutical manufacturing equipment and public utility systems (water, electricity, process gases), and for data integration with the MES system. The system provides functions including data queries, generation and printing of spreadsheets and curves, and monitoring of operating status. This helps ensure data traceability and integrity.

Manufacturing Execution System (MES)

Used to manage users and permissions involved in the production process, production-related records, production equipment, materials, and process operation procedures. This enables systematic control over the entire product production process and the electronic management of batch production records, enhances compliance and data traceability in the production process, and improves work efficiency and the level of process control.

Laboratory Information Management System (LIMS)

Used to manage the entire process of inspection samples, testing data, reagents and reference standards, testing instruments, stability studies, and environmental monitoring, forming an electronic laboratory notebook (ELN). The inspection results are integrated with the MES system, which helps enhance the reliability and traceability of data in the inspection process, improves the modernisation level of laboratory management, and reduces the risk of human error.

Medicine Safety Management

Medicine safety management is the cornerstone of safeguarding patients' lives and health. The Group strictly complied with the *Vaccine Administration Law of the People's Republic of China, Measures for the Reporting and Monitoring of Adverse Drug Reactions, Good Pharmacovigilance Practice* and other laws, regulations and document requirements, and continued to optimise our pharmacovigilance management system.

Each marketing authorisation holder in the Group has established a Drug Safety Committee, set up a dedicated pharmacovigilance department, formed an emergency response team, and developed internal management policies such as the *Emergency Management Plan for Vaccine Safety Emergencies* and the *Pharmacovigilance System Master File*, thereby strengthening our governance structure and institutional system development. The Drug Safety Committee was responsible for key responsibilities such as assessment and judgement of major risks, handling of major or emergency drug incidents, and risk control decision-making; The pharmacovigilance department was responsible for the collection, handling and reporting of information on suspected adverse drug reactions, the management of drug safety signals, the identification and assessment of drug risks, and the provision of recommendations on risk management.

The Group implemented a series of pharmacovigilance management measures before and after product commercialisation to strengthen medicine safety management.

Pharmacovigilance Management Measures of AIM Vaccine

Stage	Dimension	Management Measures
Pre-launch	Policy development	• Formulated internal management policies, such as the SOP for the Drafting and Review of the Safety Information Summary and Analysis Report During Clinical Trials, and the SOP for the Quality Management and Supervision of Outsourced Clinical PV, to standardise pharmacovigilance management. • The pharmacovigilance department formulated the Clinical Risk Management Plan based on safety information obtained during the non-clinical stage, the instructions for use of similar marketed vaccines, and safety information in relevant documents, submitted it to the CDE, and strictly implemented it in subsequent clinical trials to ensure drug safety.
	Training deployment	• Before the commencement of clinical trials, develop a Safety Management Plan. After review and approval by the clinical trial institution and the Ethics Committee, provide training to all investigators participating in the clinical trials, and implement it strictly during the clinical trials. • Conduct SOP training for the pharmacovigilance module prior to marketing, and pharmacovigilance training related to clinical trial projects.
	Compliance management	• In accordance with regulatory requirements, prepare and submit the *Development Safety Update Report* and *Aggregate Summary and Analysis Report of Safety Information During Clinical Trials,* and continuously monitor safety information related to drug risks until the drug completes clinical trials.
Post-launch	Policy development	• Added or revised multiple pharmacovigilance-related documents and standard operating procedures, including the *Pharmacovigilance System Master File* and the *Working Rules of the Vaccine Safety Committee*. At the same time, we established a pharmacovigilance quality control system across areas such as individual case safety reports, literature searches, signal detection, risk management, on-time completion rate of annual drug reports, and clinical pharmacovigilance-related work, to ensure the standardisation and efficiency of pharmacovigilance activities.
	Training deployment	• Provided basic pharmacovigilance knowledge training for all employees once a year or once every two years based on actual circumstances. • Conducted daily training for pharmacovigilance department employees in accordance with the training plan, covering pharmacovigilance regulations, documents such as SOPs, etc. • The Group's commercial and marketing team conducted annual training, covering the collection and reporting of suspected adverse events following immunisation.
Routine management	Pharmacovigilance system	• Routinely manage the pharmacovigilance system, which is used to collect, analyse, transmit, and manage pharmacovigilance-related information for products under research and development and post-marketing, enhancing the reliability of pharmacovigilance data. At the same time, it helps to identify unknown adverse drug reactions and growth trends at an early stage, supports the analysis of risk factors and possible mechanisms for adverse drug reactions, conducts quantitative analysis for risk/benefit evaluations, and releases relevant information, providing strong support for the improvement of clinical research. • In accordance with *Good Pharmacovigilance Practice* and the provisions of various SOPs, routinely conduct annual internal audits of pharmacovigilancez work during the year.

The Group continued to improve the quality management system for pharmacovigilance, established a collection and reporting mechanism for suspected adverse events following immunisation, and set up adverse reaction collection channels, including collection through medical institutions, vaccination units, the Group's commercial and marketing teams, telephone and online platforms, academic literature, post-marketing studies and programmes, and regulatory authorities. Meanwhile, the Group formulated an internal reporting process, clarified the reporting responsibilities and time limits for personnel at all levels, and ensured the timely submission of data to the National Adverse Drug Reaction Monitoring System.

All products marketed by the Group are vaccine products. In accordance with regulatory requirements, we collected and reported suspected Adverse Events Following Immunisation (AEFI) related to vaccine products, and established standardised monitoring and response procedures. After collecting AEFI from various channels, the pharmacovigilance department reported them to the local CDC in accordance with the principle of territoriality, of which serious cases were required to be reported on an expedited basis to the provincial drug regulatory authority; Subsequently, internal analysis was conducted, including ledger registration, medical coding, evaluation, and entry into the database, in order to continuously monitor and identify potential safety signals. For cases diagnosed by the CDC as adverse events following immunisation, where we agreed with the conclusion and compensation was required, financial compensation was provided; If there was any disagreement with the conclusion, an application could be made for an appraisal by the medical association, and whether compensation was provided was determined based on the appraisal conclusion.

Product Recall

Each marketing authorisation holder of the Group's products complied with the requirements of documents such as *Measures for the Administration of Drug Recalls* and established internal management policies including the *Product Recall Management Procedures,* the *Quality Incident Emergency Plan*, and the *AIM Recall Management Procedures*. In response to potential recall situations that may arise for products after commercialisation, the quality responsible person immediately initiated the product recall procedure, and relevant departments such as the Quality Assurance Department immediately initiated investigation and risk assessment processes to determine whether a recall was required. If a recall is required, a recall team will be established to develop a plan and publish the recall information within the prescribed time limits (Class I: one day, Class II: three days, Class III: seven days). During the recall process, the recall team will coordinate departments such as Customer Support and the Storage, Transportation and Distribution Department to implement product recovery, isolation identification and inventory statistics, and report to the drug regulatory authorities. The recall team will destroy the recalled products as required. The recall team will prepare a summary report after the recall is completed and implement corrective measures.

To continuously enhance emergency response capabilities, the Group established a simulated recall system and conducts a simulated recall drill once every two years to ensure the effectiveness of the recall system. During the reporting period, the Group had no product recall incidents. The Group's subsidiaries AIM Honesty and AIM Persistence organised and carried out a simulated recall drill.

Customer Service Management

Customer Service

During the customer service process, the Group attached importance to customer needs and established an in-house sales department, which was primarily responsible for sales and customer service management. The Group also formulated corresponding customer service management policies and were committed to providing customers with high-quality services. The Group's marketing team was professional and efficient. All employees took up their posts only after undergoing rigorous training and were responsible for daily sales, customer academic promotion, and the collection and feedback of market information.

The Group upheld a highly responsible attitude towards customers' rights and interests and safety, established a systematic complaint management mechanism, and formulated User *Complaint Management Procedures*, clarifying standardised processes from information registration and division of responsibilities to investigation and rectification. For each complaint, the relevant responsible department must promptly formulate response measures and conduct an in-depth root cause analysis to implement corrective and preventive measures, continuously optimising management processes.

At the same time, the Group ensured smooth communication channels with customers. Customers can provide suggestions or lodge complaints via the feedback email address, the Company's official website, telephone, and other channels. Based on the impact level and different types of customer complaints, the Company handled them in a graded manner and tracked and provided timely feedback on the handling results, thereby ensuring effective customer service management. In addition, the Group required employees, during customer visits, to focus on customer satisfaction, collect feedback from end customers, with the information collected covering aspects such as products and services, and to provide timely feedback and follow-up handling. During the reporting period, the Company did not experience any customer complaint incidents.

Responsible Marketing

The Group strictly complied with the requirements of laws, regulations, and documents such as the *Advertising Law of the People's Republic of China*, the *Drug Administration Law of the People's Republic of China*, and the *Vaccine Administration Law of the People's Republic of China*. We formulated management policies such as *Management Policy of AIM Vaccine Group for Promoter Business Management Policy*, established marketing compliance processes, stipulated and provided guidance on the Company's marketing and communication activities, and standardised responsible marketing. The Group has established a systematic and normalized responsible marketing audit system, under which the Legal Affairs and Compliance Department regularly reviews the legality and compliance of product promotional information and related publicity messaging. During the reporting period, the Group was not involved in any legal proceedings related to responsible marketing.

Enhancing Transparency of Product Information

The Group adhered to the principle of open and transparent information disclosure and strictly managed vaccine product package inserts, labelling, and packaging, truthfully indicating product ingredients, usage, contraindications, shelf life, etc., to ensure legality and compliance. During product promotion and marketing, our marketing personnel clearly explained to customers the product ingredients, sources, effects, and potential product risks, enhancing the transparency of product information while accepting supervision from a broad range of customers and consumers. The Company regularly disseminates product knowledge and epidemic prevention and control measures to consumers through channels such as social media, science popularisation activities, and customer service hotlines.

Compliant Marketing


The Group has adhered to conducting marketing activities with science and compliance at the core. In terms of organisational structure, the Group established an in-house sales department and a professional marketing team to manage and implement responsible marketing, thereby achieving resource optimisation and business synergies. In terms of channel management, the Group relied on the dual-wheel drive model of "in-house team + promotion collaboration" , strictly screened external promoters, and systematically expanded and optimised our sales network. Through ongoing communication, regular evaluations, and continuous improvements to *Management Policy of AIM Vaccine Group for Promoter Business*, the Company strengthened promoters' entry standards, compliance commitments, and conduct management to ensure that end-to-end marketing activities were standardised, transparent, and sustainable.

The Group upheld the philosophy of "past compliance, present compliance, and future compliance" , established and promoted a compliance management system, proactively learnt and studied new compliance policies and requirements with our partners, and carried out compliance communication and training. During the reporting period, the Group provided key interpretations of relevant policy documents in the medical services sector to promoters, emphasising that, on the basis of compliant operations across the entire value chain, attention should be paid to the responsibilities of each entity, penetrating management should be strengthened, and responsible marketing should be practised. In addition, the Group's in-house sales department organised monthly meeting training sessions each month to monitor market information, discuss business progress, and to learn industry- and product-related professional knowledge, thereby enhancing the professional competence of in-house sales personnel and their awareness of responsible marketing.

Meanwhile, the Group attached great importance to enhancing its partners' capabilities in responsible marketing compliance. In response to the practical needs of personnel at different levels, on the one hand, the Group organised online practical training sessions, systematically explaining key processes such as meeting management, terminal visits and data collection, and, together with case sharing and Q&A, the training cumulatively covered more than 300 attendances; On the other hand, the Group proactively visited partner enterprises to conduct on-site supervision. Through face-to-face communication, the Group jointly identified challenges in compliant operations, promoted the collaborative resolution of practical issues, and continuously enhanced the compliance execution capabilities and risk prevention and control standards of the cooperation system.



Compliant promotion


Compliant training

Information Security and Privacy Protection

The Group strictly complied with the requirements of laws, regulations and documents such as the *Data Security Law of the People's Republic of China*, the *Cybersecurity Law of the People's Republic of China* and *Regulations on Network Data Security Management*, formulated internal management policies including the *Information Security Policy*, *Security Operations and Maintenance Guidelines*, and *Network Protection Strategy*, and established an information security management structure. The Group is committed to safeguarding the information security of customers, partners and employees, and continuously improving the information security management system to ensure the compliance and stability of business operations.


Information Security Management Structure of AIM Vaccine

Information Security Leading group

Responsible for reviewing and approving the issuance of management policies, examining incident reports, and making key decisions.

Information Secuirty Working Group

Lead the development of policies, drive their implementation, and ensure timely reporting and supervision of corrective actions in the event of major incidents.



Information Security Execution Team

Responsible for strictly following established procedures for incident response, jointly enxuring the effective operation of the information security management system.

At the same time, the Group formulated SOP documents such as *Regulations on Access Rights Management for Computer Systems* and *Security Management Procedure for Computerised Systems* to standardise the approval, allocation and monitoring processes for information system access rights, clarify the security control requirements at each stage of the information system lifecycle, and strictly control access rights to customer information. In addition, to effectively prevent and respond to information system emergencies, the Group formulated the SOP for *Emergency Handling Procedures for Computerised Systems*, clarifying information security handling and data protection procedures, establishing and improving the emergency response mechanism for information systems, and effectively preventing, promptly controlling, and minimising to the greatest extent the harm and impact of various emergencies.

The Group fully understands the importance of protecting customer privacy, strictly complies with the requirements of documents such as the *Personal Information Protection Law of the People's Republic of China*, and formulated the *Employee Handbook* to set out confidentiality provisions for information such as customer records. In system design and daily operations, the Group uses customer information solely as basic system data and does not involve the collection, processing, or external provision of customers' personal privacy information, thereby strengthening personal information and privacy protection at source.

During the reporting period, the Group did not experience any incidents of data leakage or customer privacy breaches.

Supplier Management

Supplier Management

AIM Vaccine's supplier system covers three key areas: commissioned testing and research, materials and equipment, and general services. During procurement and supplier management, the Group adhered to the principles of openness, fairness, and selecting the best candidates to choose qualified suppliers, and focused on establishing long-term, stable, and mutually beneficial cooperative relationships. For suppliers in different categories, the Group established a robust supplier management system, integrating quality requirements into research and development, clinical trials, production, and other processes. The Group also prioritised selecting suppliers in the locations where we operate, actively promoting the collaborative development of local industrial chains and reducing logistics costs.

The Group strictly complied with laws and regulations such as the *Tendering and Bidding Law of the People's Republic of China,* and established internal policies including *Supplier Management Regulations* and *Material Supplier Audit Management Procedures* to standardise supplier management in terms of supplier access, supplier classification, supplier review, and supplier training.

Supplier Management Measures of AIM Vaccine

Supplier onboarding

- In the supplier onboarding process, the Group has rigorously reviewed suppliers' qualifications and onboarding documentation, assessed the completeness and authenticity of the information, and comprehensively considered suppliers' corporate reputation, litigation status, and potential risks to ensure they have no non-compliance or disciplinary records before granting supplier onboarding.
- For suppliers of critical materials, the Group has also conducted on-site audits, inspecting relevant aspects such as suppliers' materials management, manufacturing processes, production equipment management, and quality control, to ensure that onboarded suppliers meet the Group's requirements and to ensure supplier compliance and the safety of raw materials.

Supplier training

- The Group has conducted User Requirements Specification (URS) training for all suppliers to ensure that they clearly understand and meet the Group's quality and technical requirements for equipment and systems, thereby enhancing suppliers' compliance management capabilities.

Supplier classification

- Suppliers are managed on a tiered basis. Based on factors such as their business criticality, scale of cooperation, and risk rating, suppliers are classified into different categories and matched with differentiated management strategies and assessment frequencies.

Supplier audit

- Based on the risks of the materials provided by suppliers, suppliers are subject to graded management. In addition to conducting regular supplier evaluation and audits, the Group has also carried out periodic on-site audits of medium- and high-risk suppliers to ensure the authenticity and compliance of all relevant manufacturing and testing processes.
- For suppliers that are assessed through audit and evaluation as not meeting the Group's standards, the Group replaces them in a timely manner or implements supplier exit procedures, so as to safeguard the quality of supplied materials.

In addition, the Group has made the environmental friendliness of supplied materials one of the key criteria for supplier selection, identified environmental and social risks across all stages of the supply chain, and focused on reviewing suppliers' environmental protection equipment and infrastructure, such as hazardous waste treatment stations and wastewater treatment stations, as well as their occupational health management. Any non-compliant supplier is subject to a one-vote veto.

Green Procurement

To promote sustainable development of the supply chain, the Group has actively explored and implemented ESG advocacy and procurement programmes, integrated green concepts throughout the entire procurement process, and prioritised environmentally friendly suppliers and products, enhancing the sustainability of the Group' s operations.

Green Procurement Management Measures of AIM Vaccine

Sustainable procurement

- The Group has prioritised suppliers that practise environmental responsibility, clearly requiring them to establish and obtain environmental management system certification (e.g., ISO 14001), and treated such certification and related environmental performance as key additional scoring items in supplier performance evaluations, thereby incentivising supply chain partners to continuously enhance their environmental standards.

Green logistics

- The Group has used big data technologies to dynamically plan delivery routes, reducing empty vehicle mileage and fuel consumption, and effectively lowering carbon emissions during transportation.
- By introducing automated equipment, energy-saving technologies, and intelligent temperature control systems, the Group has reduced energy consumption in warehousing and improved operational efficiency.
- The Group has coordinated procurement needs and implemented a centralised procurement model, reducing logistics frequency and enhancing overall transport efficiency.



06 Green and Low-Carbon Development, Living in Harmony

Environmental Management

AIM Vaccine strictly complied with the requirements of laws, regulations and documents, including strictly complies with the *Environmental Protection Law of the People's Republic of China*, the *Law on the Prevention and Control of Atmospheric Pollution, the Water Pollution Prevention and Control Law, the Law on the Prevention and Control of Environmental Pollution Caused by Solid Wastes, the Law on the Prevention and Control of Pollution from Environmental Noise, the Measures for the Administration of Pollutant Discharge Permits*. The Group established management policies such as the *Environmental Protection Accountability Policy, Environmental Governance Management Policy* and *Environmental Protection Management Policy,* developed a sound environmental management organisational structure and institutional framework, and implemented stringent controls over the use of energy and water resources and over emissions arising from our production and operational activities. During the reporting period, AIM Honesty, AIM Persistence, and AIM Rongyu were key entities for environmental supervision by the local ecological and environmental management authorities.

The Group, guided by the ISO 14001 environmental management system standard, has continued to improve the establishment of its environmental management system. The Group organised the identification of environmental aspects, compliance reviews, internal audits, management reviews, and external audits, and continuously improved our environmental management status based on the audit results. During the reporting period, AIM Honesty passed the GB/T 24001—2016/ISO 14001:2015 Environmental Management System certification (the certificate is valid until 27 August 2028).

To address environmental emergencies, in accordance with the requirements of the Ministry of Ecology and Environment's *Notice on Issuing the Interim Measures for the Administration of Emergency Response Plans for Sudden Environmental Incidents* and *National Environmental Emergency Response Plan*, the Group engaged a third-party organisation to issue the *Risk Assessment Report on Sudden Environmental Incidents*. During the reporting period, the Group carried out emergency drills for sudden environmental incidents in accordance with the requirements set out in the environmental impact assessment and the approval. This trained employees' emergency response capabilities, enhanced skills in preventing and handling sudden environmental incidents, and reduced the potential harm to the environmental caused by such incidents.

Environmental Management Measures of AIM Vaccine

Management system development

- AIM Honesty formulated and continuously updated internal rules and regulations, including *Environmental Management System Compendium, Hazardous Waste Management Regulations, and SOP for Safe Operation of Sewage Treatment Station*, in accordance with national and local laws and regulations, to ensure that all operations are rule-based.
- AIM insisted on establishing an environmental protection leading group headed by the General Manager, defined the environmental protection department as the dedicated management body, and assigned environmental protection officers in each production department, thereby forming a three-tier management responsibility system featuring "coordination by leading group, supervision by environmental protection departments, and implementation by production departments". AIM formulated documents such as *Environmental Protection Management Policy* to ensure that all measures were effectively implemented.

Environmental emergency management

- AIM Honesty has formulated the *Emergency Response Plan for Environmental Emergencies*, clarifying emergency response procedures, division of responsibilities and post-incident evaluation requirements under different scenarios; AIM Honesty regularly organises emergency drills every year to test personnel response speed and the efficiency of information reporting, and promptly summarises and improves after the drills to enhance practical response capabilities.
- AIM Action has formulated an *emergency response plan for environmental emergencies* and regularly carries out emergency drills to enhance our capability to respond to sudden environmental incidents.
- AIM Rongyu regularly carries out emergency drills for environmental emergencies to ensure that production processes comply with environmental management requirements.

During the reporting period, the Group was not subject to any investigation by government authorities in relation to environmental violations; no new, renovated, or expanded projects had a material impact on the environment or natural resources; The Group was not subject to any significant administrative or criminal penalties, and there were no matters in which relevant government departments urged us to rectify within a specified time limit, suspend production, relocate, or shut down; no litigation was involved in relation to environmental issues or natural resources.

Resource Utilisation

Energy Management

The main energy categories involved in the Group's production and operations include direct energy such as petrol, diesel and natural gas, as well as indirect energy such as purchased electricity and steam. The above energy is mainly used in production and operations, vehicle transportation, office operations and supporting facilities.

The Group strictly complied with laws and regulations such as the *Environmental Protection Law of the People's Republic of China and the Energy Conservation Law of the People's Republic of China*, and formulated internal management policies such as *Procedures for Responsibilities for Energy Measurement Management, Procedures for the Collection, Processing, Statistical Analysis and Application of Energy Measurement Data, Energy Conservation and Emission Reduction Management System*, and *Enterprise Energy Conservation and Consumption Reduction Management System*, taking energy saving and consumption reduction and improving energy efficiency as core measures to practise green development.

The Group has promoted energy conservation and consumption reduction through routine management and target-driven initiatives, defined energy intensity as the core energy-saving target, and conveyed our sustainable development value through our achievements in green and low-carbon development.

AIM Honesty committed to reducing total energy consumption by 3% compared with the previous year under the same production volume.

AIM Rongyu committed to reducing energy consumption by 2% by 2030 compared to 2025 levels.

The Group has always regarded energy conservation, consumption reduction, and improving energy efficiency as important levers for practising the concept of green development and achieving sustainable development. Through multiple measures, including technological optimisation, energy-saving initiatives in offices, refined supervision and management, and enhanced awareness among all employees, the Group has continued to advance energy conservation and efficient energy use.

Energy Management Measures of AIM Vaccine

Production and technology optimisation

- Optimise steam demand and implement centralised steam supply and centralised use.
- Make reasonable use of cooling water pumps in the air-conditioning system as the cooling water source for process water, reduce pump start-ups, and lower energy consumption.
- Strictly implement natural gas saving requirements to avoid energy wastage.
- Strengthen the inspection, maintenance, and replacement of ageing facilities (heating, steam pipelines, etc.) in the old plant area to eliminate leaks, spills, drips, and seepage.
- Coordinate the layout of the research, development, and application of new energy-saving technologies, formulate a dedicated energy management plan, regularly assess progress in energy consumption reduction efforts, and enhance the professionalisation of energy management.
- With energy-saving technologies and equipment upgrades as the core, optimise the clean energy layout and adjust the energy consumption structure.

Energy-saving awareness enhancement

- Strengthen energy-saving training and communications for employees, reinforce energy-saving awareness among all staff, and promote the integration of energy-saving concepts into day-to-day operations.

Office and daily energy conservation

- Promote the use of information systems and paperless office practices.
- Advocate daily energy-saving behaviours such as turn off lights when leaving and promptly switch off heating and air conditioning. During periods of high summer temperatures, promote working from home for administrative personnel and set air-conditioning temperature to 26° C.
- Implement retrofitting of lighting facilities and promote the use of energy-saving facilities such as solar street lights and LED energy-saving lamps. For newly purchased equipment, give priority to products with tier-one energy efficiency.
- AIM Action has deployed rooftop photovoltaic systems to increase the use of clean energy and improve its production energy consumption structure. In 2025, electricity generated from its photovoltaic system was approximately 2,380 MWh.

Measurement and monitoring

- Install additional metering equipment to refine the supervision of energy use across various pipelines and levels.
- Establish a mechanism for the collection, processing, statistical analysis and application of energy metering data, to achieve refined management of energy use.
- Implement whole-process control over direct energy sources such as petrol, diesel and natural gas, as well as indirect energy sources such as electricity and steam.

Water Resource Utilisation

All water used in the Group's production and operations was sourced from the municipal water supply system. The water source was stable, and the supply was reliable, with no risks associated with water withdrawal. Water withdrawal was mainly used in production processes, cleaning of production equipment and clean areas, supporting utilities, office and domestic use, site landscaping, fire-fighting, and other activities.

The Group strictly complied with the requirements of laws, regulations, and documents such as the *Water Law of the People's Republic of China* and the *Law of the People's Republic of China on the Prevention and Control of Water Pollution*, established internal management policies such as the *Water Use Metering Management Policy*, and continuously improved water use efficiency and the level of water resource recycling and utilisation. At the same time, the Group established and improved its water resources management system, clarified water conservation targets, and proactively disclosed the progress and effectiveness of water resources management to stakeholders.

AIM Honesty committed to achieving a 3% reduction in water use intensity by 2030 compared with the 2025 baseline.

AIM Rongyu committed to achieving a 2% reduction in water use intensity by 2030 compared with the 2025 baseline.

The Group optimised its water use structure through a range of measures, including improving water-saving technologies, enhancing the reuse of water resources, installing water-saving facilities, and adopting air-cooled/water-cooled air-conditioning chiller units. At the same time, we improved the water metering and monitoring system to achieve refined management of water use across all stages, ensuring a stable water supply and improved efficiency. During the reporting period, the Group's water intake management was compliant and orderly, and no material non-compliance incidents related to water resources occurred.

Water Resource Management Measures of AIM Vaccine

Reuse of water resources	• AIM Honesty reused reclaimed water in good faith for employees' shower water, used condensate water from heatingexchange as make-up water for the heating system circulating water, and carried out make-up water heat exchange through the boiler flue gas cooler to improve water resource utilisation efficiency. • AIM Action increased water resource reuse by using wastewater generated by the purified water machine to irrigate lawns, realising wastewater resource utilisation. • AIM Persistence used the cooling circulating water system to enhance water recirculation efficiency.
Water-saving device installation	• AIM Honesty installed water metering instruments in the workshops, monitored water consumption daily, and promptly identified and repaired water leakage. • AIM Persistence installed metering instruments and regularly recorded and cross-checked meter readings, achieving digitalised management of water use. • AIM Rongyu's plants installed new water meters to monitor water use energy consumption at each stage and refine oversight of the use of each water-use branch line.
Optimisation of water-saving technologies	• AIM Honesty used air-cooled chiller units for air-conditioning refrigeration to reduce the demand for cooling water, and installed reactive power compensation devices to improve electricity use efficiency, thereby indirectly reducing water consumption in the energy production process. • AIM Action carried out a technical retrofit of the cooling tower balance pipe to optimise water use efficiency of the cooling system. • AIM Persistence installed automatic taps in workshops to limit water usage, thereby reducing water consumption at the point of use.
Water conservation training	• AIM Rongyu enhanced publicity on water conservation, promoting water-saving behaviours to become an internalised, conscious practice among employees.

Raw Materials and Packaging Materials Management

The raw materials required for the Group's production mainly included core vaccine active and excipient materials, as well as various laboratory reagents and consumables, which were primarily used in key processes such as vaccine research and development, manufacturing preparation, and quality testing.Packaging materials were mainly categorised into primary packaging that comes into direct contact with pharmaceuticals, such as vials, prefilled syringes, rubber stoppers and aluminium caps, and secondary packaging for finished products, such as cartons, labels, package inserts, cushioning materials and cold-chain protective packaging materials. These were mainly used in vaccine filling and sealing, finished product packaging, warehousing and storage, and cold-chain logistics transportation.

To ensure compliant management throughout the full life cycle of raw materials and packaging materials, the Group continued to improve its management policies and systems for product raw materials and packaging. Through supplier screening, evaluation audits, and tiered management, we ensured stable quality of raw materials and packaging materials purchased and delivered to our facilities, in compliance with regulatory requirements. At the same time, we strengthened supply chain security and traceability, reasonably controlled inventory, reduced quality risks, and improved management efficiency.

The Group and its subsidiaries have attached great importance to full life-cycle management of raw materials. AIM Honesty has formulated multiple management policies, including *Material Supplier Evaluation and Approval SOP, Procurement Planning Management SOP, Procurement Management SOP, Material Reception Management SOP, Material Storage Management SOP, Material Issuance Management SOP, and Hazardous Goods Receipt, Storage and Issuance SOP*, and has also established a comprehensive supplier evaluation and approval process. Based on qualification requirements such as quality, environmental, occupational health and safety, and certifications for the quality management system of suppliers of pharmaceutical packaging materials, as well as the Drug Manufacturing Licence, Printing Business Licence, Hygiene Permit for Disinfection Product Manufacturing Enterprises, Food Production Licence, Hazardous Chemicals Business Licence, National Industrial Product Production Licence, and Work Safety Permit, AIM Honesty has implemented graded management of materials used in production, with the raw material certification ratio at approximately 90%.

The Group has strengthened the refined management and control of packaging materials, set annual unit consumption targets for packaging materials used in the production process, and promoted precise management of the production process. Taking AIM Honesty as an example, by ensuring production continuity and precisely controlling production processes, in early 2025, it set the unit consumption quota for labels, cartons and package inserts at 1.01 units/bottle, with actual consumption at 1.01 units/bottle, successfully achieving the predetermined target.

Emissions Management

Pollutant Management

The Group strictly complied with the requirements of laws, regulations and documents such as the *Environmental Protection Law of the People's Republic of China, the Law of the People's Republic of China on the Prevention and Control of Water Pollution, the Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution, the Law of the People's Republic of China on the Prevention and Control of Pollution from Environmental Noise and Measures for the Administration of Pollutant Discharge Permits*. The Group established internal management policies such as the *Energy Conservation Regulation* to implement end-to-end control over emissions of waste gas, wastewater and noise generated during our production and operation activities. Meanwhile, the Group strictly complied with the Hong Kong Stock Exchange's *Guidelines on Environmental Key Performance Indicators Reporting*, to ensure the accuracy and transparency of emissions data, and made disclosures based on the information released on the National Pollutant Discharge Permit Management Information Platform.

The Group committed to maintaining a 100% compliance rate for wastewater, waste gas and noise emissions.

In wastewater management, the Group implemented classified treatment and online monitoring for key categories of wastewater pollutants, including ammonia nitrogen, chemical oxygen demand, total nitrogen, and suspended solids, to ensure compliant wastewater discharge. During the reporting period, the Group's wastewater discharge compliance rate reached 100%.

Wastewater Management Measures of AIM Vaccine

Intelligent monitoring and compliance control

- Install a 24-hour real-time online wastewater monitoring system to monitor various wastewater indicators and upload the data to the Ecology and Environment Bureau website.
- AIM Honesty installed an online monitoring device at the main wastewater discharge outlet to monitor pollutant concentrations and discharge data in real time and connect to the local environmental protection department's regulatory platform. Meanwhile, AIM Honesty engaged a third-party institution to conduct periodic manual sampling and monitoring. All monitoring data were entered into the Liaoning Province Monitoring Information Release Platform to ensure compliance with national and local discharge standards at all times.
- AIM Action has established a wastewater treatment station equipped with an online monitoring device, which is connected to the local environmental protection department's regulatory platform. AIM Action also worked with third parties to carry out periodic sampling, operation and maintenance.

Sorted disposal and resource recovery

- Implement the rain and sewage separation system, the rainwater is collected and discharged into the rain pipe, and finally into the municipal rain pipe network.
- AIM Persistence ensures that wastewater generated during research and development, production and operations is treated at the sewage treatment station before being discharged in compliance with standards. Domestic sewage is pre-treated via grease traps and septic tanks before being discharged into the urban sewage pipe network. Phenol- and ethanol-containing waste liquids are collected separately and handed over to qualified third-party organisations for recycling and treatment.
- AIM Honesty employs a 'equalisation tank–coagulation and sedimentation–anoxic–contact oxidation' process to treat wastewater, which is discharged into the municipal sewerage network once it meets regulatory standards.

In terms of waste gas management, the Group focused on major waste gas emission categories such as nitrogen oxides (NO_x), sulphur dioxide (SO_2), Non-methane hydrocarbons (NMHC), particulate matter (PM), and developed dedicated treatment plans through an enhanced emission reduction management system to ensure that gases emitted during production and R&D processes are clean. During the reporting period, the Group achieved a 100% compliance rate for waste gas emissions.

Waste Gas Management Measures of AIM Vaccine

Technological upgrading and purification treatment

- Equip facilities including boiler flue gas waste-heat recovery devices, canteen flue gas purification devices, fermentation tank exhaust gas filtration devices, and exhaust gas filtration devices for biosafety cabinets in the microbiology laboratory. The exhaust gas is discharged through dedicated pipelines after purification treatment.
- Exhaust gas from the animal housing facility and the hazardous waste storage warehouse is treated by a two-stage activated carbon adsorption device and then discharged through a 15 m exhaust stack.
- All exhaust gas outlets are connected to treatment systems; specifically, exhaust gas from the wastewater treatment plant is treated using a photo-catalytic oxidation and activated carbon system, whilst fermentation exhaust gas is treated via an alkali scrubber and activated carbon system. Organic exhaust gas is treated by activated carbon adsorption to remove organic compounds.

Targeted emissions reduction

- By employing ultra-low-nitrogen burners and recirculation systems to improve combustion efficiency, nitrogen oxide emissions are kept below 30 mg/L; optimising the air-fuel ratio and reducing heat loss from flue gas further reduces overall exhaust emissions.
- A comprehensive energy-saving and emissions-reduction programme is implemented through the emissions management system to ensure that emissions from production and R&D processes remain consistently clean.

In terms of noise management, the Group ensured that noise emissions met the required standards through reasonable planning and refined controls. The Group reasonably planned the plant layout, keeping noise sources away from the plant boundary and sensitive buildings, and regularly commissioned qualified third-party testing organisations to conduct manual sampling and monitoring. During the reporting period, the Group achieved a 100% compliance rate for noise emissions.

Waste Management

The Group strictly complied with laws, regulations and document requirements such as the *Solid Waste Pollution Prevention and Control Law*, and formulated internal management policies including *Environmental Facility Management Regulations, Hazardous Waste Management Regulations, Medical Waste Management Regulations, Solid Waste and Hazardous Waste Management System, Hazardous Waste Pollution Prevention and Control Responsibility System,* and *Emergency Response Plan for Hazardous Waste Accidents*, to standardise management processes for the classification, collection, transfer and disposal of hazardous and non-hazardous waste.

Types of Waste and Disposal Methods of AIM Vaccine

Type		Disposal Methods
Non-hazardous waste	Waste cardboard boxes, waste plastics, domestic waste from office buildings, and kitchen waste from the canteen, etc.	• Designate clearly defined classified storage areas within the plant premises and post signage to promote resource recycling and reuse. • Reuse decommissioned wooden pallets from warehousing, prioritise the procurement of refillable-ink pens, and promote double-sided printing of paper to minimise the final volume of waste requiring disposal to the greatest extent possible.
Hazardous waste	Laboratory waste liquids, waste packaging containers for chemical raw materials and strains, expired raw materials, waste fluorescent tubes, etc.	• Establish dedicated storage areas for hazardous waste; after weighing, affix a QR code label to the outside of the packaging for identification purposes. • Implement a systematic management approach involving designated personnel, categorised storage, weighing and recording, and labelling; and regularly entrust entities holding a *Hazardous Waste Management Licence* to carry out safe disposal. • Collect waste liquids such as phenol and ethanol in designated containers and hand them over to a qualified third-party organisation for recycling and disposal.

The Group upheld the principles of energy conservation and waste reduction, embedded whole-process control throughout all aspects of production, research and development, and daily operations, and implemented scientific and standardised disposal of various types of waste. At the same time, the Group encouraged each subsidiary to set waste discharge volume targets and waste reduction targets in line with its own development realities and to continuously improve resource recycling and waste reduction effectiveness, contributing to the achievement of sustainable development.

The Group committed to maintaining a 100% compliant waste disposal rate.

Response to Climate Change

AIM Vaccine had a profound understanding of the far-reaching impacts of climate change, and proactively took measures to address climate challenges, actively responding to the national strategic policy of carbon peaking and carbon neutrality. The Group systematically assessed and managed climate risks across four dimensions: governance, strategy, risk management, and metrics and targets. By continuously optimising our climate governance framework, deepening green technology innovation, and enhancing resource utilisation efficiency, the Group continuously strengthened our capability to address climate change, endeavoured to reduce our carbon footprint in operations, and contributed to achieving the national dual carbon goals.

Governance

The Group strengthened the top-level design of our climate change management system, clarified responsibilities and division of labour, and comprehensively coordinated and advanced our energy-saving and carbon reduction efforts.

AIM Vaccine's Governance Structure for Response to Climate Change

Decision-making level	• As the highest decision-making body for ESG and response to climate change, the Board of Directors is responsible for reviewing and approving climate change-related strategies, targets, and management policies, and overseeing climate-related risks and opportunities.
Management level	• The ESG working group is responsible for organising, coordinating, and advancing climate change-related work, formulating specific work plans and implementation measures, and following up on the implementation progress of various departments and subsidiaries.
Execution level	• All functional departments and subsidiaries are responsible for implementing specific climate change-related work, including, but not limited to, the implementation of energy-saving and emissions reduction measures, and the monitoring and reporting of carbon emissions data, and promptly reported work progress to the ESG working group.

Strategy

The Group attaches great importance to the risks and opportunities arising from climate change. The Group has systematically carried out climate risk assessments and opportunity identification, and established identification and assessment procedures for climate-related risks and opportunities. Through policy research, peer benchmarking, and in conjunction with expert opinions, we analysed the climate-related risks and opportunities faced by us and our value chain upstream and downstream over the short, medium, and long term, assessed their financial impacts, and formulated response measures as well as corresponding climate change management strategies for physical risks and transition risks.

AIM Vaccine' s Climate Change-Related Risks and Opportunities as well as Management Strategies

Type	Specific Description	Scope of Impact	Potential Financial Impact	Management Strategies
List of Risks				
Physical risks	Acute physical risks: Extreme weather events such as heavy rain, snowstorms, typhoons, extreme low temperature, and extreme heat may trigger secondary disasters like landslides, mudslides, power outages, and urban flooding. These can negatively impact company operations, raw material storage, production, inventory, and labour costs, leading to asset losses or business disruptions.	Short term	Increase in operating costs Decrease in revenue	• Regularly monitor weather conditions, establish emergency response plans, and conduct emergency drills to enhance crisis management capabilities. • Regularly inspect and maintain emergency equipment and facilities to ensure ability to respond to natural disasters. • Consider climate risks and geographic factors when selecting operational sites to mitigate potential natural disaster risks. • Improve processes, upgrade production equipment, optimize energy structures, and enhance production efficiency to reduce operating costs. • Accelerate green and low-carbon product upgrades and supply chain carbon footprint optimisation, and strengthen the communication of the brand' s green value and the alignment mechanism for customers' sustainable needs.
	Chronic physical risks: Climate change-induced temperature fluctuations, rising sea levels, and water shortages may increase transportation costs and pose severe challenges to coastal operation sites.	Medium and long term	Increase in operating costs	
Transition risks	Policy and regulatory risk: Strengthened environmental regulations at both international and domestic levels may impose stricter carbon emission limits. Failure to comply with evolving policies could lead to legal liabilities, administrative penalties, or increased operational costs.	Short, medium, and long term	Increase in operating costs	
	Technical risk: Advancements in environmental and energy-saving technologies may impose financial burdens when purchasing eco-friendly equipment or undergoing low-carbon transitions.	Short, medium, and long term	Increase in operating costs	
	Reputational risk: Against the backdrop of increasingly stringent requirements from regulators, investors, customers, and consumers regarding corporate climate performance, if the Company demonstrates inadequate climate information disclosure or lagging emissions reduction actions, negative feedback from stakeholders may increase.	Medium and long term	Increase in operating costs Decrease in operating revenue	
List of Opportunities				
Resource efficiency opportunity	Promote the upgrading of energy-saving technologies, optimise energy management practices, and enhance energy efficiency, thereby reducing energy costs and improving operational performance.	Short, medium, and long term	Decrease in operating costs	• Give priority to the use of environmentally friendly materials and select high-quality environmentally friendly suppliers to reduce the environmental impact across the full product life cycle at source. • Carry out energy-saving and consumption-reduction initiatives. Optimise equipment operation and advance technology upgrades to unlock energy-saving potential and reduce energy consumption. • Continue to focus on the use of renewable energy, and proactively explore application solutions for clean energy such as solar and wind power.
Energy source opportunity	Increase the proportion of renewable energy usage, reduce our reliance on fossil fuels, avoid the impacts caused by fluctuations in fossil fuel prices, and help the Company build a green and low-carbon brand image.	Short, medium, and long term	Decrease in operating costs	

Note: Short term refers to within one year (inclusive) after the end of the reporting period, medium term refers to one to five years (inclusive), and long term refers to more than five years.

Risk Management

The Group has established a sound climate change risk management process. Through three core steps, namely risk identification and assessment, risk prioritisation and response, and risk monitoring and control, we continuously reduce the impact of climate risks on the Company and stakeholders, and enhance climate resilience.

Climate Change Risk Management Process of AIM Vaccine

Risk Identification and Assessment	• Based on industry characteristics, policy changes, and stakeholder needs, we conducted analyses of both physical risks and transition risks, assessed their potential impact on the Company, and ensured that the evaluation was scientific and reliable.
Risk Prioritisation and Response	• Based on the level of impact of climate-related risks and opportunities, we established a prioritisation mechanism, classifying them into minor, and key risks and opportunities. Minor risks are incorporated into routine monitoring, while response measures are formulated for key risks and opportunities, with management strategies continuously optimised.
Risk Monitoring and Control	• We incorporated climate risk monitoring into the Company's overall risk management processes, and conducted regular assessments and reviews of risk levels to ensure that risks remain controllable. The ESG working group regularly assesses risk conditions and reports to the Board of Directors, providing a basis for management to adjust or enhance management strategies.

In response to physical risks arising from climate change, the Group established systems including *Special Emergency Plan for Extreme Weather Disasters and the On-Site Typhoon and Flood Prevention Response Plan*, which clarify organisational safeguards for emergency management and are applicable to personal injuries and equipment damage incidents caused by natural disasters such as typhoons, rainstorms, thunderstorms, and earthquakes within the Company's area. When typhoons, lightning strikes, etc. lead to leakage incidents or fire and explosion accidents, *Emergency Plan for Leakage Incidents* and the *Emergency Plan for Fire and Explosion Incidents* and other plans are activated simultaneously, forming a multi-scenario coordinated emergency response mechanism.

At the same time, the Group strengthened the maintenance and upgrading of operational equipment in a targeted manner to enhance its resilience to extreme weather conditions. During the reporting period, AIM Vaccine's plants positioned sandbags in advance at key protection points to prevent flood disasters and, based on the terrain and equipment characteristics, raised the equipment by 30cm-50cm to address potential waterlogging disasters that may be caused by rainwater.

To effectively address the transition risks arising from climate change, based on an analysis of the Group's greenhouse gas emissions structure over the years, we have identified improving energy use efficiency, optimising the energy mix, and promoting the use of renewable energy as the core directions for the Group's greenhouse gas emissions reduction. The specific management measures mainly include production and technological optimisation, office and daily energy conservation, metering and supervision, and awareness raising. For details, please refer to the "Energy Management" section.

Metrics and Targets

The Group identified and analysed greenhouse gas emissions generated across all business segments, and clarified that greenhouse gas emissions in the operational segments mainly comprise direct (Scope 1) greenhouse gas emissions arising from the consumption of petrol, diesel and natural gas, indirect (Scope 2 and Scope 3) greenhouse gas emissions arising from purchased electricity used in production and office operations, as well as employee commuting. Given that Scope 3 emissions involve numerous upstream and downstream links in the value chain, data collection is more difficult, and the basis for collaborative accounting with external parties is not yet well developed, the Group is currently unable to comprehensively and accurately compile statistics on and account for Scope 3 greenhouse gas emissions. In 2025, the Group's Scope 3 greenhouse gas emissions disclosure primarily covered emissions related to employee commuting. Going forward, we will continue to improve the data collection mechanism and progressively advance related management and disclosure work. For details of the relevant carbon emission data, please refer to the “ESG Data Tables and Notes” section.

Building on this, the Group focused on its own operational level and formulated clear climate change-related targets such as carbon emissions intensity, serving as an important reference and guide for carrying out energy conservation and emissions reduction efforts. We also actively advocated that employees, suppliers, and partners jointly practise green and low-carbon concepts, bringing together multi-stakeholder efforts to jointly advance the achievement of carbon reduction targets.

AIM Honesty committed to achieving a 5% reduction in carbon emissions intensity by 2030 compared with the 2025 baseline.



07 People-Centred Approach, Empowering Employees

Employee Recruitment and Rights

Employee Recruitment and Employment

AIM Vaccine upheld the concept of equal employment and diversity in employment, strictly complied with the requirements of laws, regulations, and documents including the *Labour Law of the People's Republic of China* and the *Labour Contract Law of the People's Republic of China*, and formulated and implemented internal management systems such as the *Employee Handbook* to ensure that the entire employee recruitment and employment process was lawful and compliant.

The Group's recruitment channels include campus recruitment and social recruitment. In terms of campus recruitment, the Group adjusted its recruitment activities in a timely manner in accordance with the market environment. Through university job fairs or setting up campus recruitment booths, and by signing cooperation agreements with universities, we built a talent pool to meet future needs. In terms of social recruitment, the Group has channels such as internal referrals, recruitment via our official website, recruitment platforms, headhunting firms, and social media software. During the recruitment process, the Group strictly based talent hiring on the job qualifications and candidates' overall capabilities, providing each aspiring individual with equal employment opportunities and a broad development platform.

The Group has always based its selection on objective facts and actively attracted diverse talent, without allowing factors such as gender, age, nationality, marital and parental status, disability status, race, ethnicity, or religious belief to affect the outcome of talent selection. At the same time, the Group strictly carried out qualification reviews of recruitment candidates during the hiring process, and resolutely prohibited the employment of child labour and forced labour. The Group has opposed forced labour in the *Employee Handbook*, implemented stringent reviews for overtime work. During the reporting period, no incidents occurred within the Group involving employee discrimination, the employment of child labour, forced labour, or other violations of labour laws and regulations.

During the reporting period, the Group entered into labour contracts with employees in accordance with the law. There were no penalties by the relevant authorities for infringing employees' rights and interests.

Employee Rights, Interests and Benefits

The Group has established a standardised employment management system to comprehensively safeguard employees' lawful rights and interests. The Group formulated and implemented internal management systems such as the *Compensation Management Policy*. Following the principle of position value orientation, we established an employee compensation and benefits system to effectively safeguard employees' basic rights and interests, including working hours, rest and leave, and social insurance, and to build a harmonious labour relationship.

In terms of non-compensation benefits, the Group set up various activities covering all employees and regularly organised a diverse range of cultural and sports activities to enhance employees' sense of belonging and wellbeing.

AIM Vaccine Employee Rights, Interests, and Benefits

Social insurance

- Make full and timely contributions for employees to pension insurance, medical insurance, unemployment insurance, work injury insurance and maternity insurance, as well as the housing provident fund.

Working hoaurs

- Implement the standard working hour system, working eight hours per day and 40 hours per week.
- Encourage employees to improve work efficiency. If overtime is required, approval must be applied for and obtained from the direct line manager, and overtime pay is paid in accordance with national regulations.
- Provide a flexible working system for employees in non-sales positions.

Rest and leave

- Formulated the *Vacation Management Policy*, under which employees were entitled to statutory holidays, annual leave, marriage leave, maternity leave, paternity leave, breastfeeding leave, personal leave, and other types of leave.

Compensation management

- Establish a remuneration management system, pay remuneration in full to all employees on a monthly basis, and, in light of the market, the Group's financial position, and the results of employees' performance appraisal, make equitable salary adjustments.

Benefits

- Provide supplementary medical insurance for all active full-time permanent employees.
- Provide housing allowances to all functional employees.
- Provide an RMB100 birthday gift to employees on their birthdays.
- Provide an RMB500 customary gift for employees' marriage, childbirth, and the death of immediate family members.
- In terms of providing assistance to employees in difficulty, the Group proposed donating more than RMB77,000 to employees in difficulty in 2025.
- The trade union regularly distributes labour protection supplies on a quarterly basis.

Care for female employees

- Provide maternity condolence payments to female employees.
- Give female employees festival gifts on International Women's Day.

Cultural and sports activities

- AIM Rongyu organised the third Fun Sports Games.
- In December 2025, AIM Persistence organised the AIM Leadership & AIM Craftsman basketball tournament.
- In December 2025, the biotech trade union of AIM Honesty organised the third Employee Poetry Recitation Competition.



AIM Action distributed labour protection supplies



AIM Rongyu' s trade union, in collaboration with the Xinqi Subdistrict General Trade Union, launched the "Trade Union Takes You to Draw a Blind Box"



AIM Rongyu joined forces with the community to carry out activities such as free distribution of Laba porridge, free distribution of Fu, and free oral health consultations.



AIM Rongyu visited an injured employee in hospital



AIM Persistence' s AIM Leading & AIM Craftsman Basketball Tournament



AIM Honesty hosted a poetry recitation competition

In addition, the Group strictly prohibits forced labour, discrimination, and other behaviours that infringe upon employees' lawful rights and interests. If employees experience or witness relevant incidents, they may submit a complaint through the internal platform in writing or by telephone. The Company undertook to keep the reported content and the whistleblower' s identity strictly confidential, and would not disclose any information without authorisation, thereby effectively safeguarding employee privacy; any conduct involving potential suppression, retaliation, discrimination, or unfair treatment would be subject to a serious investigation and handled in accordance with laws and regulations.

Flowchart of AIM Vaccine' s Employee Complaint Handling Process



The Group attached importance to democratic communication with employees, fostered an equal and harmonious working culture, implemented the fundamental system of democratic management, gave full play to the roles of the democratic appraisal meeting and the employees' representative assembly, among others, built a communication bridge between employees and the Company, and enhanced employee satisfaction. The Group's subsidiaries AIM Rongyu, AIM Honesty, AIM Persistence and AIM Action have all established trade unions. In 2025, AIM Honesty completed departmental award nominations through the Employees' Representative Congress, while AIM Action completed the re-election of its Trade Union Committee and Employees' Representative Congress.

Democratic Management and Communication System of AIM Vaccine

Democratic appraisal system	• Organise regular communications between employees and the Company's management. • The trade union organises democratic appraisal meetings. • Scope of review: business policies, personnel transfers, compensation reform, etc.
Employee representative meetings	• Participate in revisions to policies covering employees' compensation and benefits, working hours and leave, occupational safety, special protections for female employees, and social security benefits.

In 2025, various departments across the Group conducted employee satisfaction surveys to systematically collect employee feedback across dimensions including the working environment, career development, organizational culture, work motivation, well-being, and stress. The surveys covered 100% of employees in the relevant departments, with a 100% questionnaire response rate. The results indicated that employees generally recognized the Group's growth opportunities and team atmosphere, while also putting forward specific suggestions for improving the office environment. Based on the survey findings, the Group promptly implemented corrective and optimization measures, including the provision of heaters, air purifiers, first-aid kits, ergonomic chair, and other equipment, to continuously improve workplace conditions, effectively respond to employee concerns, further enhance employee experience and well-being, and strengthen employees' sense of happiness, belonging, and organizational cohesion.

Human Capital Development

Employee Training

AIM Vaccine has attached great importance to the development of employees' potential and capability enhancement, and established a systematic employee career development and training management system. The Group strictly complied with relevant laws and regulations, including the *Labour Law of the People's Republic of China*, the *Vocational Education Law of the People's Republic of China* and the *Labour Contract Law of the People's Republic of China*, and formulated internal management policies such as the *Programme of Annual Employee Training Planning* to safeguard employees' legitimate rights and interests.

The Group has established an organisational structure for human capital management. The Human Resources Department took the lead in setting up the employee training system and coordinating resources, working in collaboration with various business departments to implement training initiatives, thereby ensuring employees' multi-channel development.

The Group has established a systematic talent training system and developed the Sailing Programme, Endurance Programme, and Leadership Programme, covering training for new employees, leadership training for management, professional training, and general skills training, thereby supporting the development of internal talent pipelines within the Group.

AIM Vaccine Training System

Training Category	Trainees	Training Methods and Contents	Training Cycle
Sailing Programme	Newly hired employees	• Deliver training through intensive lectures. • General functional staff: Company-related content, financial compliance, and an introduction to integrity. • Sales staff: Company-related content, knowledge and skills for business roles, product introduction, and an introduction to financial compliance and integrity.	Quarterly training
Endurance Programme	Middle and senior management personnel	• Deliver theoretical foundation through intensive lectures. • Conduct on-site visits to deepen understanding of scenarios. • Conduct simulation drills to strengthen practical operational capabilities.	Annual training
	Outstanding employees		
	Fresh graduates		
Leadership Programme	All senior management personnel and relevant business unit heads	• Consolidate theoretical foundations through intensive lectures. • Conduct forum sharing and discussions to spark a clash of ideas. • Conduct immersive simulation drills to hone practical skills.	Annual training

Case

Conducting management trainee training for graduates from higher education institutions

The Group has attached importance to building a talent pipeline of university graduates and established a comprehensive management trainee development system. The Group has formulated and implemented the *Management Trainee Management Measures*, providing structured training programmes with a duration of 3 to 12 months for outstanding fresh graduates. The Group adopts a combined model of "unified instruction + mentoring by supervisors + job rotation", clarifying mentor selection criteria, core responsibilities, and incentive mechanisms, while also establishing a communication and feedback mechanism involving multiple stakeholders. Through quantitative assessments, promotion arrangements, job rotation placements, and an elimination mechanism, the Group ensured the quality and suitability of talent development.

To enhance the leadership capabilities of the Group's management and improve the overall competencies of management personnel, the Group organised leadership training programmes for senior management, middle management, and junior management. The training courses covered training on operational decision-making and strategic planning, advanced leadership development and mindset training, and management knowledge and project management skills training, among others, with a view to enhancing managers' strategic thinking, decision-making capabilities and team leadership, and laying a solid foundation for the Company to build a high-performing leadership pipeline.

The Group encourages employees to enhance their professional capabilities by obtaining various professional qualification certifications. We regularly organise relevant training courses to empower employees and have introduced benefits such as examination leave to help employees further improve their capabilities.

Employee Performance Assessment and Promotion

AIM Vaccine attaches great importance to employee development and promotion. AIM Vaccine formulates personalised career plans for employees at different levels, clarifying career objectives, development directions and training pathways, supported by comprehensive training. AIM Vaccine implements differentiated development strategies tailored by level and category, designing bespoke career development blueprints for employees at different levels and clearly defining their growth pathways.

The Group has established multi-channel career development pathways, dividing positions into five major job families: Management (M), Technology (T), Sales and Marketing (S), Function (F), and Production (P). Each job family includes job grades from junior to senior, as well as job tiers A, B and C, thereby creating a comprehensive career development framework. Employees may deepen their expertise and progress through vertical promotion within their own professional track, accumulating greater professional depth; Employees may also, after reaching a certain level, achieve cross-track lateral development based on their capabilities and development direction. This mechanism has facilitated the growth pathway for the Group's professional talent and also provided a clear roadmap for cultivating multi-disciplinary management talent, enabling win-win development for employees and the Group.

The Group measured employees' work performance through a performance appraisal system, clarified work tasks and standards, and enhanced employees' work motivation and sense of responsibility. Functional teams underwent annual performance appraisals, sales teams underwent quarterly performance appraisals based on actual performance, and employees of subsidiaries were appraised based on production cycles and other factors, providing an appraisal basis for remuneration distribution, talent promotion and talent development.

In terms of performance feedback, the Group has established a sound performance feedback and appeal mechanism. If employees have objections to their appraisal results, they may submit an appeal in writing or through online channels. The Human Resources Department will review whether the appraisal results are consistent with the employees' actual performance, ensuring an open and transparent appeal process and effectively safeguarding employee rights and the fairness of performance appraisal.

In addition, the Group successively launched a number of equity incentive schemes to incentivise employees, Directors and consultants who had made outstanding contributions to the Group's development. These schemes aimed to fully mobilise the initiative and sense of belonging of core personnel, build development synergy, and support the Group's business to achieve sustained and healthy growth.

Work Safety

Work Safety Management

AIM Vaccine regards production safety as its top priority. It has established and continuously improved its safety management system and standardised operating procedures, created a safe and healthy working environment for employees, and effectively ensured employees' health, production safety, and the stable and reliable quality of its products. The Group strictly complied with the requirements of laws, regulations and documents such as the *Production Safety Law of the People's Republic of China*, the *Fire Control Law of the People's Republic of China* and the *Regulations on the Safe Management of Hazardous Chemicals*, formulated internal management policies such as Management Procedures for Environmental Safety Accident Emergency Handling and Biological Safety Management Manual, improved the system of safety production management policies, and ensured the safety of production and operations.

In terms of organisational structure, the Group established a Safety Management Committee and set up a Work Safety Office and a Work Safety Leading Group. The Safety Management Committee is responsible for decision-making and overall planning across all production stages, the Work Safety Office is responsible for advancing work safety management and coordinating cross-departmental safety work, and the Work Safety Leading Group is responsible for implementing major safety matters. Each production subsidiary, on the basis of complying with the Group's rules and regulations, has established safety production management SOPs such as the *Hazard Identification, Rectification and Safety Inspection Management Policy* and the *Safety Training and Education Management Policy*, continuously standardising the Company's safety production management work.

In addition, the Company established a comprehensive emergency response plan system, including special plans for fire and explosion accidents, chemical leakage accidents, and natural disaster accidents. It also conducted emergency drills for relevant employees on biosecurity, special equipment safety, fire safety, and exposure to accidental incidents, effectively safeguarding employee safety.

Work Safety Management Structure of AIM Vaccine

Safety Management Committee	Coordinate overall safety management efforts, and be responsible for decision-making and planning for each stage of production.
Work Safety Office	Promote work safety management, coordinate cross-departmental safety work, and supervise the implementation of major safety matters.
Work Safety Leading Group	Implement the Group' s safety requirements to ensure end-to-end safety across production, equipment and facilities, and personnel.

The Group attaches great importance to production safety and has adopted systematic, multi-faceted production safety and management measures, covering safety management aspects such as biosafety management, fire safety management, and contractor construction safety management. This has established a solid safety line of defence and continuously enhanced safety management standards.

Work Safety Management Measures of AIM Vaccine

Biological safety

- Establish a Biosafety Committee to develop and improve the biosafety management system.
- Assess and file records on the hazards of pathogenic microorganisms involved in laboratories.
- Carry out routine laboratory inspections on a regular basis.
- Provide comprehensive biosafety protective equipment, including portable eyewash units, protective face shields, cleanroom garments, etc.
- Equip laboratories with emergency response kits to address unexpected accidental injuries.

Fire safety

- Equip comprehensive fire-fighting facilities.
- Regularly inspect and optimise fire access routes to ensure they remain clear and unobstructed.

Construction safety

- Develop internal control documents such as the *Contractor Management System and Special Operations Management System.*

The Group remained committed to the principle that "everyone is responsible for safe production". The Group' s subsidiaries established a comprehensive safety management system, delivered specialised training in areas including emergency drills, biosafety, supplier safety, and fire safety, and, in parallel, advanced integrated EHS training, continuously strengthening employees' safety awareness and management standards.

Work Safety Management Measures for Subsidiaries of AIM Vaccine

- AIM Persistence established a safety management system for risk identification, monitoring, and prevention.
- AIM Honesty carries out inspections twice daily, once in the morning and once in the afternoon, at key locations such as the oxygen manifold room and hazardous chemicals warehouse. It has also conducted fire drills and evacuation drill training, and promoted safety production warning messages.
- AIM Action regularly conducts laboratory safety training for departments to strengthen biosafety management.
- AIM Rongyu conducts monthly safety warning education and emergency drills.



AIM Honesty carries out fire drills



AIM Honesty' s evacuation drill training



AIM Honesty' warning notices on the LED display



AIM Action conducts laboratory safety training for departments

Occupational Health and Safety

The occupational disease hazard factors for AIM Vaccine involve biological, chemical and physical factors, including viruses, bacteria and biological allergens, the volatilisation of chemical materials and highly irritant chemicals, as well as noise, high temperatures, power frequency electric fields, etc.

The Group has attached great importance to employees' occupational health and safety, and established and improved an occupational health and safety management system. The Group strictly complied with laws and regulations such as the *Law of the People's Republic of China on the Prevention and Treatment of Occupational Diseases* and the *Provisions on Supervision and Administration of Occupational Health in Workplaces*, formulated management policies including the *Biological Safety Management Manual* and the *Laboratory Safety Management Procedures*, and set annual occupational health targets, including zero fatal occupational injury accidents, zero fire accidents, and zero occupational disease incidents, to ensure the effective implementation of occupational health management measures.

At the same time, the Group's manufacturing subsidiaries provide employees with comprehensive occupational disease risk protection measures in terms of engineering controls and equipment management, routine prevention and control, and regular occupational health examinations.

Occupational Health Management Measures for AIM Vaccine's Manufacturing Subsidiaries

AIM Honesty

- **Engineering Controls and Equipment Management:** With the Level 3 standardised safety management system in the pharmaceutical industry as the core, we improved on-site control measures. Through measures such as isolation, zoned operations, ventilation, provision of personal protective equipment, and noise reduction, we reduced the frequency of exposure and adopted pipelining, among other measures, to reduce employees' exposure to occupational hazard factors to within the limit values, thereby safeguarding employees' health and safety.

AIM Persistence

- **Routine Prevention and Control:** In 2025, we organised managerial personnel to participate in competency training for biosafety management professionals in pathogenic microorganism laboratories, enhancing occupational health and safety awareness.

AIM Rongyu

- **Routine Prevention and Control:** We arrange for employees who are in contact with viruses to receive rabies vaccinations at designated sites; provide labour protection supplies (e.g., protective gloves, safety goggles, etc.) to employees in special positions; regularly organise occupational health training.
- **Regular Occupational Health Check-ups:** We arrange occupational health medical check-ups for employees.

AIM Action

- **Daily Prevention and Control:** We completed the detection of occupational hazard factors in production workshops, installed occupational hazard notification signs on-site, and provided safety protection facilities and equipment.
- **Regular Occupational Health Check-ups:** We conducted occupational health check-ups for employees.

As of the end of the reporting period, AIM Honesty obtained the ISO45001 occupational health and safety management system certification. During the reporting period, the occupational disease medical examination rate for employees was 100%, with no occupational diseases or suspected cases identified, and no employee work-related injury or fatality incidents occurred.



AIM Honesty obtained the ISO45001 Occupational Health and Safety Management System Certification

08 Committed to Public Welfare, Making Health Care Accessible

Community Investment and Public Welfare

The Group strictly complied with laws and regulations such as the *Charity Law of the People's Republic of China* and the *Law of the People's Republic of China on Donation for Public Welfare*, and actively fulfilled corporate social responsibility based on its mission in the field of public health. The Group steadily improved the accessibility of public health services and contributed to the development of society's health initiatives by carrying out professional health education, donating testing reagents and vaccines, and participating in regional special initiatives to eliminate viral hepatitis.

Health Education

As an enterprise deeply rooted in the vaccine sector, the Group has consistently integrated health promotion and public health responsibility into our operational practices, strengthened the public health system through professional training, driven technological iteration through academic seminars, and enhanced public awareness through science popularisation initiatives, thereby supporting regional infectious disease prevention and control and the advancement of health equity on multiple fronts.

Overview of AIM Vaccine Health Education Activities

Activity Theme	Cooperation Entities	Key Measures	Outcomes
AIM Lecture Hall online education	Peking University	On 25 April 2025, guest speakers were invited to share their views on the current hepatitis A prevention and control efforts.	Enhanced the professional awareness of relevant personnel regarding the current situation and strategies for HAV prevention and control, and supported the dissemination and popularisation of knowledge on HAV prevention and control.
	Department of Infectious Diseases, Jiangsu Province Hospital	On 28 July 2025 (the 15th World Hepatitis Day globally), experts were invited to deliver an online lecture themed HBV infection and liver cancer prevention: from mechanisms to precision prevention and treatment.	Popularised professional knowledge on hepatitis B virus infection and liver cancer prevention, enhanced relevant personnel's level of understanding of precision prevention and treatment of HBV, and contributed to hepatitis prevention and control and health promotion.
	Peking University People's Hospital Emergency Surgery Department/ Trauma Treatment Centre, former Division of Infectious Disease Control and Prevention of the Chinese Center for Disease Control and Prevention, AIM Rongyu	On 28 September 2025 (the 19th World Rabies Day), authoritative experts were invited to interpret rabies epidemic trends, key challenges in prevention and control, and vaccine breakthroughs, promoting the "three-step approach" for post-exposure scientific management and providing guidance on vaccination precautions for special populations.	Enhanced public awareness of rabies prevention and control as well as self-protection capabilities, and promoted the establishment of a collaborative prevention and control system involving government, professional institutions, enterprises, and the public.
Professional training on prevention and control of animal-related injuries	Suzhou CDC, CDCs of various districts and counties, heads of emergency departments at key hospitals	A themed training session was held on 24 May 2025 to share the latest diagnosis and treatment technologies, policy standards, and product solutions in the field of animal injury, and to establish a professional platform for exchange and empowerment.	Enhanced the professionalism and standardisation of regional animal bite injury diagnosis, treatment, and prevention and control, and strengthened public health emergency response capabilities.

Activity Theme	Cooperation Entities	Key Measures	Outcomes
Academic seminar on the prevention and control of viral hepatitis	Disease control and prevention institutions in Tangshan, heads of key outpatient departments	An academic seminar was organised on 27 May 2025, focusing on the latest developments in the prevention of viral hepatitis, interpreting the key points of the Guidelines for the Prevention and Treatment of Chronic Hepatitis B, and promoting updates to regional hepatitis B prevention and control technologies as well as the sharing of experience.	Enhanced the professional competence and prevention and control awareness of hepatitis B prevention and control practitioners in the Tangshan area, laying a professional foundation for regional efforts to eliminate viral hepatitis.
AIDS, Syphilis and HBV promotion campaign in schools	Tangshan University, Tangshan Municipal CDC	On 16 October 2025, CDC professionals were organized to visit the campus and public science education and publicity on AIDS, syphilis and HBV were carried out, helping university students advance HBV prevention and control efforts.	Enhanced young people's awareness of infectious diseases and their self-protection capabilities, and built a health protection barrier on campus.

Public Welfare and Charity

The Group has actively engaged in public welfare and charitable undertakings, extended its public health responsibilities to a broader range of social contexts, and, through concrete actions, helped to improve the accessibility and equity of public health services, thereby fulfilling our corporate social responsibilities.

Overview of AIM Vaccine's Public Welfare and Charity Activities

Themes of Public Welfare Initiatives	Cooperation Entities	Key Measures	Outcomes
Public welfare support for the action to eliminate HBV	Tangshan Health Commission, CDC, Infectious Disease Hospital	The Group participated in the launch meeting of the HBV elimination programme themed integration of medical care and prevention, and medical-prevention collaboration on 28 May 2025, and donated testing reagents to provide material support for HBV screening.	Supported Tangshan City in accelerating progress towards eliminating HBV, improving the accessibility of public health services, and promoting health equity.
Public welfare donations for eliminating viral hepatitis	Fengnan District Health Commission, Education Bureau, and Hepatitis Foundation	In May 2025, the Group donated hepatitis B testing reagents to Fengnan District through the Hepatitis Foundation and participated in the special campaign for proactive testing to eliminate HBV.	Supported the implementation of HBV screening in Fengnan District, helped advance the plan to eliminate viral hepatitis at the primary level, and enhanced the capacity of primary-level public health services.
Public welfare donations for recombinant HBV vaccine	Red Cross Society, public health institutions in Guangdong Province	In 2025, AIM Honesty donated recombinant HBV vaccine worth approximately RMB37 million to Guangdong Province through the Red Cross Society.	Improved the accessibility of hepatitis B vaccines and supported regional efforts to eliminate viral hepatitis.
Testing reagent donations for AIDS, Syphilis and HBV	Tangshan University, Tangshan Municipal CDC	On 16 October 2025, the Group donated testing reagents to Tangshan University to support efforts to eliminate HBV among university students.	Enhanced the capacity to guarantee supplies for HBV prevention and control on campus, and promoted the development of campus health initiatives.

Access to Healthcare

AIM Vaccine has long been committed to the global health cause, and has continued to make efforts in major public health disease areas such as hepatitis, rabies and meningitis, providing strong support for access to health through practical actions.

Under the access to healthcare topic, the Group established a relevant organisational structure, with the Board of Directors of the Group serving as the highest responsible body for the medical and access to healthcare topic. The Board of Directors is responsible for overseeing the implementation and supervision of the Group's medical and access to healthcare strategy, whilst the ESG working group is responsible for the day-to-day management and implementation of this topic.

As a major private vaccine group in the PRC with a full-industry chain, AIM Vaccine has been deeply engaged in the human vaccine sector for more than ten years. Its product offerings encompass both routine and non-routine immunisation vaccines, and its products are distributed across all 31 provinces, autonomous regions and municipalities, ensuring extensive coverage throughout the country. As of the end of the reporting period, the Company had eight commercialised vaccines in six disease areas, as well as 20 innovative vaccine candidates under development in 12 disease areas. The Company's products in production and under development broadly covered all vaccine products ranked in the world's top ten (by global sales in 2020), proactively supporting access to health.

AIM Vaccine's 2025 Initiatives to Support Access to Healthcare

Product accessibility

- Continue to deepen our presence in the domestic market, and distribute vaccine products to county-level CDCs through cold-chain logistics, enhancing vaccine accessibility in remote areas.

Price affordability

- Adopt customised pricing solutions to promote fair vaccine pricing, thereby enhancing vaccine affordability.

Technological R&D and innovation

- Actively carry out technological R&D and innovation, develop Serum-Free Rabies Vaccines, High-Potency Human Diploid Cell Rabies Vaccine, 20-valent Pneumonia Conjugate Vaccine, mRNA RSV Vaccine, and mRNA Shingles Vaccine, strive to fill market gaps, meet the needs of relevant populations, and enhance vaccine safety, promoting access to health care.
- Against the backdrop of the absence of any specifically approved vaccine on the market for Coxsackievirus A16, one of the major pathogens causing hand, foot and mouth disease (HFMD), and the emergence of outbreak trends in certain regions, the Group has been actively advancing the research and development of a bivalent inactivated vaccine for hand, foot and mouth disease. Covering two major circulating strains, the vaccine has entered Phase I clinical development.

International cooperation and technology transfer

- Actively expand our international perspective and advance overseas business layout, engage in exchanges and cooperation with governments and local enterprises in developing countries, accelerate the dissemination of our knowledge and experience through efficient technology transfer, facilitate the widespread application of advanced and reliable R&D and manufacturing technologies in developing countries, and contribute to the improvement of global health and well-being.


Promoting vaccine exports

Case

To accelerate the internationalisation of our products, the Group has established overseas registration arrangements for its existing product pipeline, promoting vaccine exports to developing countries. In 2025, the Group successfully exported its ACYW135 Meningococcal Polysaccharide Vaccine to Egypt, Tajikistan and Burkina Faso, and actively pursued market access in candidate countries such as Indonesia, Belarus, Côte d' Ivoire and Kenya. Subsequent products currently in development, such as the 13-valent Pneumonia Polysaccharide Conjugate Vaccine, are also undergoing registration procedures in countries such as Kenya, laying the groundwork for the international market strategy for these future products.

The Group has promoted Chinese vaccine to the world, providing strong support for the health of local populations in developing countries and contributing to global public health, which is conducive to building a global community of health for all.





Export shipment

Conducting educational activity on disease prevention and control

Case

In May 2025, the Group, together with authoritative institutions such as the Tangshan Municipal CDC and Infectious Disease Hospital, jointly carried out a public health awareness campaign themed "Medical and Prevention Integration, and Medical and Prevention Collaboration". As one of the partners, the Group actively participated and donated HBV testing reagents to support local HBV prevention and control efforts, helping to enhance regional health service standards. This campaign not only demonstrated the Group's commitment to social responsibility in public health, but also, through professional science popularisation and the extension of services to the grassroots level, enhanced end customers' understanding of disease prevention, further consolidating their trust in the value of the Group's products and services. It contributed to access to healthcare and achieved a win-win outcome of both social benefits and deepened user relationships.





ESG Data Tables and Notes

Governance Data Tables and Notes

Economic Performance Data Table

Disclosure Item	Unit	2025
Operating revenue	RMB10,000	116,567.30

Business Ethics Data Table

Disclosure Item	Unit	2025
Number of directors receiving anti-commercial bribery and anti-corruption training	person	9
Proportion of directors receiving anti-commercial bribery and anti-corruption training	%	100
Average duration of anti-commercial bribery and anti-corruption training received per director[1]	hour	1.34
Number of employees receiving anti-commercial bribery and anti-corruption training	person	1,466
Proportion of employees receiving anti-commercial bribery and anti-corruption training	%	100
Average duration of anti-commercial bribery and anti-corruption training received per employee[2]	hour	1.34
Number of corruption litigation cases brought against the issuer or its employees and concluded during the reporting period	case	0
Number of incidents during the reporting period where the Company' s unfair competition behaviour resulted in litigation or major administrative penalties	case	0
Amount involved in litigation or major administrative penalties during the reporting period arising from the Company' s unfair competition practices	RMB10,000	0

Note 1: Average duration of anti-commercial bribery and anti-corruption training received per director = Total duration of anti-commercial bribery and anti-corruption training received by directors / Number of directors receiving anti-commercial bribery and anti-corruption training.

Note 2: Average duration of anti-commercial bribery and anti-corruption training received per employee = Total duration of anti-commercial bribery and anti-corruption training received by employees / Number of employees receiving anti-commercial bribery and anti-corruption training.

Environmental Data Tables and Notes

Environmental Management Data Table

Disclosure Item	Unit	2025
Number of incidents in which penalties resulted from violations of environmental protection laws and regulations	case	0

Resource Utilisation Data Table[1]

Disclosure Item	Unit	2025
Comprehensive energy consumption[2]	tce	16,639.64
Comprehensive energy consumption intensity[2]	tce/RMB10,000	0.14
Direct energy consumption[3]	tce	4,041.23
Gasoline consumption by mobile sources	L	49,313.39
Diesel consumption by mobile sources	L	10,479.72
Diesel consumption for stationary sources	tonnes	0.10
Natural gas consumption	m^3	2,988,269.00
Indirect energy consumption[4]	tce	12,598.41
Purchased electricity consumption	MWh	44,306.23
Electricity consumption from renewable energy sources	MWh	2,380
Purchased steam consumption	GJ	209,269.45
Purchased electricity consumption intensity[5]	MWh/RMB10,000	0.38
Percentage of renewable energy consumption[6]	%	1.76
Water consumption	ton	1,170,359.42
Water consumption intensity[7]	ton/RMB10,000	10.04
Total consumption of packaging materials for finished products	ton	364.99

Note 1: The Company's environmental data statistical scope includes four manufacturing subsidiaries: AIM Rongyu, AIM Honesty, AIM Persistence, and AIM Action.

Note 2: The total comprehensive energy consumption compiled by the Company is disclosed in tonnes of standard coal. The unit conversion factors refer to *China Energy Statistical Yearbook*, *GB/T 2589—2020 General rules for calculation of the comprehensive energy consumption*. Comprehensive energy consumption intensity = Comprehensive energy consumption / Operating revenue.

Note 3: The Company's direct energy mainly includes gasoline by mobile sources, diesel by mobile sources, diesel for stationary sources, and natural gas.

Note 4: The Company's indirect energy consumption mainly includes purchased electricity and purchased steam. Electricity consumption from renewable energy sources refers to the green electricity purchased by the Company.

Note 5: Intensity of purchased electricity consumption = purchased electricity consumption / operating revenue.

Note 6: Percentage of renewable energy consumption = electricity consumption from renewable energy sources / total energy consumption × 100%.

Note 7: Water consumption intensity = Water consumption / Operating revenue.

Emissions Management Data Table[1]

Disclosure Item	Unit	2025
Total exhaust gas emissions[2]	10,000 m^3	3,287
Total Non-methane hydrocarbon (NMHC) emissions	kg	18,174.35
Particulate matter (PM) emissions	kg	506.73
Nitrogen oxide (NO_X) emissions	kg	995.39
Sulphur oxides (SO_X) emissions	kg	212.61
Total wastewater discharge[3]	m^3	142,334.57
Chemical oxygen demand (COD) emissions	ton	2.82
Biochemical oxygen demand (BOD) emissions	ton	1.76
Suspended solids (SS) emissions	ton	2.43
Total nitrogen emissions	ton	0.53
Ammonia nitrogen (NH_3-N) emissions	ton	0.07
Total hazardous waste[4]	ton	119.52
Total non-hazardous waste[5]	ton	94.96

Note 1: The Company' s environmental data statistical scope includes AIM Rongyu, AIM Honesty, AIM Persistence, and AIM Action.

Note 2: The main air pollutants in the Company' s exhaust gas are Non-methane hydrocarbons (NMHC), nitrogen oxides (NO_X), and sulfur oxides (SO_X).

Note 3: The main pollutants in the Company' s wastewater are chemical oxygen demand (COD), biochemical oxygen demand (BOD), suspended solids (SS), total nitrogen, and ammonia nitrogen (NH_3-N). The data on pollutant discharges in wastewater were all based on third-party routine wastewater testing reports and calculated accordingly.

Note 4: The Company' s hazardous waste mainly includes laboratory waste liquids, packaging containers for chemical raw materials and strains, expired raw materials, waste fluorescent tubes, etc.

Note 5: The Company' s non-hazardous waste mainly includes waste cardboard boxes, waste plastics, domestic waste from office buildings, and kitchen waste from the canteen, etc.

Response to Climate Change Data Table[1]

Disclosure Item	Unit	2025
Total greenhouse gas emissions (Scope 1 and Scope 2)[2]	tCO_2e	53,168.36
Greenhouse gas emissions intensity (Scope 1 and Scope 2)[2]	tCO_2e/RMB10,000	0.46
Scope 1 GHG emissions	tCO_2e	6,639.83
Scope 2 GHG emissions	tCO_2e	46,528.53
Scope 3 GHG emissions[3]	tCO_2e	527.76

Note 1: The Company's environmental data statistical scope includes AIM Rongyu, AIM Honesty, AIM Persistence, and AIM Action.

Note 2: Scope 1 Greenhouse gas emissions include direct greenhouse gas emissions arising from natural gas consumption, petrol and diesel consumption by official vehicles, diesel consumption from stationary sources, and natural gas consumption. For 2025, the greenhouse gas emission factors for petrol and diesel used by official vehicles refer to *Guidelines for the Preparation of Provincial Greenhouse Gas Inventories (Trial)* (2011), *GB 17930-2016 Gasoline for motor vehicles, Guidelines for Greenhouse Gas Emission Accounting and Reporting for Land Transportation Enterprises (Trial)*, and *China Energy Statistical Yearbook* (2023). The greenhouse gas emission factors for natural gas refer to the Ministry of Ecology and Environment's *Guidelines on Enterprises Greenhouse Gas Emissions Accounting and Reporting — Power Generation Facilities* (2022) and *China Energy Statistical Yearbook* (2023). The greenhouse gas emission factors for diesel from stationary sources refer to *Guidelines for the Preparation of Provincial Greenhouse Gas Inventories (Trial)* (2011) and *China Energy Statistical Yearbook* (2023). Scope 2 Greenhouse gas emissions mainly comprise indirect greenhouse gas emissions arising from purchased electricity and purchased heat. For 2025, the carbon emission factor for purchased electricity referred to the national average electricity carbon dioxide emission factor of 0.5306tCO_2/MWh in the Ministry of Ecology and Environment and the National Bureau of Statistics *Announcement on the Release of 2023 Power Sector CO_2 Emission Factors*, and adopted 0.6tCO_2e/MWh from the *Hongkong Electric Holdings Limited Sustainability Report 2024*. Total Greenhouse gas emissions = Scope 1 Greenhouse gas emissions + Scope 2 Greenhouse gas emissions.

Note 3: Scope 3 greenhouse gas emissions mainly refer to indirect greenhouse gas emissions generated by employee commuting. The emission factor for Scope 3 greenhouse gas emissions is 0.36 tCO_2e/person. The average commuting distance is sourced from the *2024 China Major Cities Commuting Monitoring Report*, the average number of commuting days is based on the annual number of working days (250 days), the average commuting mode is sourced from the *2024 Urban Transportation Travel Survey*, and the greenhouse gas emission factors for various modes of transport are sourced from Appendix 5, *Beijing Carbon Inclusion Project Management Requirements*, to the *Notice of the Beijing Municipal Ecology and Environment Bureau on Properly Conducting the Management of Carbon Emission Entities and Carbon Emissions Trading in Beijing in 2024.*

Social Data Tables and Notes

Employee Recruitment and Rights Data Table

Disclosure Item		Unit	2025
Total employees		person	1,466
By gender	Male	person	747
	Female	person	719
By age	Aged over 50	person	96
	Aged 30 to 50	person	946
	Aged below 30	person	424
By employment type	Under full-time labour contract system	person	1,448
	Under full-time labour dispatch system	person	10
	Part-time	person	0
	Others (rehired after retirement/internship)	person	8
By region	Mainland China	person	1,466
	Hong Kong, Macau, Taiwan, and overseas	person	0

Disclosure Item		Unit	2025
By grade	Frontline	person	1,295
	Middle management	person	133
	Senior management	person	38
Number of employees turnover		person	177
By gender	Male	person	94
	Female	person	83
By age	Aged over 50	person	16
	Aged 30 to 50	person	62
	Aged below 30	person	99
By region	Mainland China	person	177
	Hong Kong, Macau, Taiwan, and overseas	person	0
Employee turnover rate[1]		%	12.07
By gender	Male	%	12.58
	Female	%	11.54
By age	Aged over 50	%	16.67
	Aged 30 to 50	%	6.55
	Aged below 30	%	23.35
By region	Mainland China	%	12.07
	Hong Kong, Macau, Taiwan, and overseas	%	0
Number of incidents penalised for violating laws and regulations related to employee employment and labour		case	0
Number of incidents penalised for violating laws and regulations related to employee recruitment and dismissal		case	0
Number of incidents penalised for violating laws and regulations related to employee working hours and leave		case	0
Number of incidents penalised for violating laws and regulations related to employee promotion and equal opportunity		case	0
Number of incidents penalised for violating laws and regulations related to employee anti-discrimination and diversity		case	0

Note 1: Employee turnover rate for a certain category = Number of employee turnover in that category / Total number of employees in that category × 100%.

Human Capital Development Data Table

Disclosure Item		Unit	2025
Total number of employees receiving training		person	1,272
By gender	Male	person	659
	Female	person	613
By grade	Frontline	person	1,133
	Middle management	person	113
	Senior management	person	26
Employee training coverage rate[1]		%	86.77
By gender	Male	%	88.22
	Female	%	85.26
By grade	Frontline	%	87.49
	Middle management	%	84.96
	Senior management	%	68.42
Total training duration for employees		hour	38,501.42
By gender	Male	hour	18,992.60
	Female	hour	19,508.82
By grade	Frontline	hour	34,878.60
	Middle management	hour	3,040.10
	Senior management	hour	572.72
Average training duration per employee[2]		hour	30.26
By gender	Male	hour	28.82
	Female	hour	31.83
By grade	Frontline	hour	30.78
	Middle management	hour	26.90
	Senior management	hour	22.03

Note 1:Training coverage rate of employees in a certain category = Number of employees trained in that category / Total number of employees in that category × 100%.

Note 2:Average training duration for employees in a certain category = Total training duration for employees in that category / Total number of employees trained in that category.

R&D and Innovation Data Table

Disclosure Item	Unit	2025
Number of major projects under development	project	20
Number of R&D personnel	person	398
Proportion of R&D personnel	%	27.15
R&D investment	RMB10,000	35,608.73
Proportion of R&D investment in operating revenue	%	30.55
Number of patent applications during the reporting period	piece	14
Number of granted patents during the reporting period	piece	31
Number of active patents	piece	189

Product Safety and Quality Data Table

Disclosure Item	Unit	2025
Total number of complaints received regarding products and services	case	0
Handling rate of complaints received regarding products and services	%	100
Number of major safety and quality liability incidents related to products and services during the reporting period	case	0
Amount involved in major safety and quality liability incidents related to products and services during the reporting period	RMB10,000	0

Data Table for Information Security and Privacy Protection

Disclosure Item	Unit	2025
Number of confirmed incidents of customer data leakage, theft, or loss	case	0

Supplier Management Data Table

Disclosure Item		Unit	2025
Total number of suppliers[1]		supplier	375
By region	Number of suppliers in Mainland China	supplier	320
	Number of suppliers in Hong Kong, Macao, Taiwan, and overseas regions	supplier	55
Number of supplier evaluation conducted during the reporting period		time	263
Number of suppliers that conducted environmental and social impact assessments		supplier	172
Number of suppliers assessed for environmental and social impacts		supplier	172
Number of suppliers that agreed to make improvements after the environmental and social impact assessment		supplier	0

Note 1: The total number of suppliers was calculated to include AIM Rongyu, AIM Honesty, AIM Persistence, and AIM Action

Work Safety Data Table

Disclosure Item	Unit	2025
Number of workdays lost due to work-related injuries	day	127.88
Number of employees who died due to work-related injuries	person	0
Average number of working days lost per employee due to work-related injuries[1]	day/person	0.09
Proportion of employees who died due to work-related injuries	%	0

Note 1: Average number of working days lost per employee due to work-related injuries = Number of working days lost due to work-related injuries / Total number of employees.

Community Investment and Public Welfare Data Table

Disclosure Item	Unit	2025
Number of employees participating in volunteer services	person	115
Total duration of employees participating in volunteer services	hour	1,048
Average duration per employee participating in volunteer services	hour	31
Amount of charitable donations	RMB10,000	603

Benchmarking Index Table

Benchmarking Index Table of HKEX's *Environmental, Social and Governance Reporting Rules*

Part B: Mandatory Disclosure Requirements	
Mandatory Disclosure Item	Corresponding Section of this Report, Other Explanations
Governance structure	ESG Governance Structure
Reporting Principles	Report Preparation Explanation
Reporting Boundary	Report Preparation Explanation
Part C: "Comply or explain" Provisions	
Subject Areas, Aspects, General Disclosures and KPIs	Corresponding Section of this Report, Other Explanations
Subject Area A. Environmental	
Aspect A1. Emissions	
General Disclosure A1	Environmental Management Emissions Management Response to Climate Change
KPI A1.1	Emissions Management ESG Data Tables and Notes
KPI A1.3	ESG Data Tables and Notes
KPI A1.4	ESG Data Tables and Notes
KPI A1.5	Environmental Management Emissions Management
KPI A1.6	Environmental Management Emissions Management
Aspect A2. Use of Resources	
General Disclosure A2	Environmental Management Resource Utilisation
KPI A2.1	ESG Data Tables and Notes
KPI A2.2	ESG Data Tables and Notes
KPI A2.3	Environmental Management Energy Management
KPI A2.4	Environmental Management Resource Utilisation
KPI A2.5	ESG Data Tables and Notes

Part C: "Comply or explain" Provisions	
Subject Areas, Aspects, General Disclosures and KPIs	Corresponding Section of this Report, Other Explanations
Aspect A3. The Environment and Natural Resources	
General Disclosure A3	Environmental Management
KPI A3.1	Environmental Management
Subject Area B. Social	
Employment and Labour Practices	
Aspect B1. Employment	
General Disclosure B1	Employee Recruitment and Rights Human Capital Development
KPI B1.1	ESG Data Tables and Notes
KPI B1.2	ESG Data Tables and Notes
Aspect B2. Health and Safety	
General Disclosure B2	Work Safety
KPI B2.1	ESG Data Tables and Notes
KPI B2.2	ESG Data Tables and Notes
KPI B2.3	Work Safety Occupational Health and Safety
Aspect B3. Development and Training	
General Disclosure B3	Human Capital Development
KPI B3.1	ESG Data Tables and Notes
KPI B3.2	ESG Data Tables and Notes
Aspect B4. Labour Standards	
General Disclosure B4	Employee Recruitment and Rights
KPI B4.1	Employee Recruitment and Rights
KPI B4.2	Employee Recruitment and Rights
Operating Practices	
Aspect B5. Supply Chain Management	
General Disclosure B5	Supplier Management
KPI B5.1	ESG Data Tables and Notes
KPI B5.2	Supplier Management
KPI B5.3	Supplier Management
KPI B5.4	Supplier Management

Part C: "Comply or explain" Provisions	
Subject Areas, Aspects, General Disclosures and KPIs	Corresponding Section of this Report, Other Explanations
Aspect B6. Product Responsibility	
General Disclosure B6	Product Safety and Quality Customer Service Management Information Security and Privacy Protection
KPI B6.1	ESG Data Tables and Notes
KPI B6.2	Customer Service Management
KPI B6.3	Intellectual Property Protection
KPI B6.4	Product Safety and Quality
KPI B6.5	Information Security and Privacy Protection
Aspect B7. Anti-corruption	
General Disclosure B7	Business Ethics
KPI B7.1	Business Ethics ESG Data Tables and Notes
KPI B7.2	Business Ethics
KPI B7.3	Business Ethics ESG Data Tables and Notes
Community	
Aspect B8. Community Investment	
General Disclosure B8	Community Investment and Public Welfare
KPI B8.1	Community Investment and Public Welfare
KPI B8.2	Community Investment and Public Welfare ESG Data Tables and Notes

Part D: Climate-related Disclosures	
Climate-related disclosures	Corresponding Section of this Report, Other Explanations
(i) Governance	
19. Governance	Response to Climate Change - Governance
(II) Strategy	
20. Climate-related risks and opportunities	Response to Climate Change - Governance
21. Business model and value chain	Response to Climate Change - Governance
22-23. Strategy and decision-making	Response to Climate Change - Governance

Part D: Climate-related Disclosures	
Climate-related disclosures	Corresponding Section of this Report, Other Explanations
(II) Strategy	
24-25. Financial position, financial performance and cash flows	The Group was unable to separately identify the expected financial impacts of climate-related risks or opportunities. We only assessed the financial impacts of climate-related risks and opportunities on the Group through qualitative judgement. For details, please refer to the section Response to Climate Change - Strategy.
26. Climate resilience	Due to our limited current capabilities and resources, the Company was temporarily unable to fully carry out a climate resilience assessment. After prudent consideration, the Company applied the capability relief mechanism during the reporting period. It will continue to enhance our capabilities in identifying and managing climate-related risks and opportunities, and disclose climate resilience-related information in a timely manner in subsequent disclosure cycles.
(III) Risk Management	
27. Risk management	Response to Climate Change - Risk Management
(IV) Metrics and Targets	
28-29. Greenhouse gas emissions	ESG Data Tables and Notes - Environmental Data Tables and Notes
30. Climate-related transition risks	The Group has identified the key types of transition risks, physical risks and opportunities, and discribe the relevance to business and assets. However, given that, at this stage, it is difficult to reliably measure the amounts and proportions relating to specific assets or business activities, the Group has not disclosed quantitative proportions but has provided qualitative disclosures instead.
31. Climate-related physical risks	
32. Climate-related opportunities	
33. Capital deployment	The Group has not yet compiled statistics on the amount of capital expenditure, financing or investment used for climate-related risks and opportunities.
34. Internal carbon prices	The Group has not yet applied a carbon pricing mechanism in decision-making.
35. Remuneration	The Group has not yet incorporated climate-related factors into its compensation policy.
36. Industry-based metrics	Medical Research Ethics - Clinical Trial Safety Access to Healthcare
37-40. Climate-related targets	Response to Climate Change - Metrics and Targets
41. Applicability of cross-industry metrics and industry-based metrics	Given that the information currently held by the Group that can be used to assess areas where climate risks or opportunities are concentrated is limited, the statistical results of cross-industry metrics involve significant uncertainty. Therefore, in accordance with relevant requirements and under the prudence principle, the Group has adopted a reasonable information exemption, and will reassess the cross-industry metrics once information is sufficiently enhanced.

AIM Vaccine

Full Industry Chain Vaccine Group

AIM Vaccine Co., Ltd.

Email: aim.securities@aimbio.com
Address: 26/F, Building T6, Han' s Plaza, 2 Ronghua South Road,
Economic-Technological Development Area, Beijing
Website: https://www.aimbio.com